{"400b0a445eab93a838851de5589e51d5b008fdb6": [["B R I E F R E P O R TMassTag Polymerase-Chain-Reaction Detection of Respiratory Pathogens, Including a New Rhinovirus Genotype, That Caused Influenza-Like Illness in New York State during [2004] [2005] In New York State during winter 2004, there was a high incidence of influenza-like illness that tested negative both for influenza virus, by molecular methods, and for other respiratory viruses, by virus culture.", [["Influenza-Like Illness", "DISEASE", 140, 162], ["influenza-like illness", "DISEASE", 270, 292], ["influenza virus", "DISEASE", 323, 338], ["respiratory viruses", "DISEASE", 376, 395], ["influenza virus", "ORGANISM", 323, 338], ["influenza virus", "SPECIES", 323, 338], ["influenza virus", "SPECIES", 323, 338], ["B R I E F R E P O R TMassTag Polymerase", "TEST", 0, 39], ["Respiratory Pathogens", "PROBLEM", 68, 89], ["a New Rhinovirus Genotype", "TREATMENT", 101, 126], ["Influenza", "PROBLEM", 140, 149], ["influenza", "PROBLEM", 270, 279], ["influenza virus", "PROBLEM", 323, 338], ["other respiratory viruses", "PROBLEM", 370, 395], ["virus culture", "TEST", 400, 413], ["Respiratory Pathogens", "OBSERVATION", 68, 89], ["New", "OBSERVATION_MODIFIER", 103, 106], ["Rhinovirus", "OBSERVATION", 107, 117], ["influenza", "OBSERVATION", 270, 279], ["respiratory", "ANATOMY", 376, 387], ["viruses", "OBSERVATION", 388, 395]]], ["Concern that a novel pathogen might be implicated led us to implement a new multiplex diagnostic tool.", [["a novel pathogen", "PROBLEM", 13, 29], ["a new multiplex diagnostic tool", "PROBLEM", 70, 101]]], ["MassTag polymerase chain reaction resolved 26 of 79 previously negative samples, revealing the presence of rhinoviruses in a large proportion of samples, half of which belonged to a previously uncharacterized genetic clade.", [["samples", "ANATOMY", 72, 79], ["samples", "ANATOMY", 145, 152], ["Tag", "GENE_OR_GENE_PRODUCT", 4, 7], ["samples", "CANCER", 72, 79], ["rhinoviruses", "ORGANISM", 107, 119], ["samples", "CANCER", 145, 152], ["MassTag polymerase chain reaction", "PROBLEM", 0, 33], ["rhinoviruses", "PROBLEM", 107, 119], ["chain", "OBSERVATION_MODIFIER", 19, 24], ["rhinoviruses", "OBSERVATION", 107, 119], ["large", "OBSERVATION_MODIFIER", 125, 130]]], ["In some instances, knowledge of the detected viral and/or bacterial (co)infection could have altered clinical management.B R I E F R E P O R TInfluenza-like illness (ILI), a nonspecific respiratory illness defined as fever 138\u040aC with cough and/or pharyngitis, is tracked by the Centers for Disease Control and Prevention (CDC) Influenza Surveillance System.", [["infection", "DISEASE", 72, 81], ["TInfluenza-like illness", "DISEASE", 141, 164], ["ILI", "DISEASE", 166, 169], ["respiratory illness", "DISEASE", 186, 205], ["fever", "DISEASE", 217, 222], ["cough and/or pharyngitis", "DISEASE", 234, 258], ["Influenza", "DISEASE", 327, 336], ["the detected viral", "PROBLEM", 32, 50], ["bacterial (co)infection", "PROBLEM", 58, 81], ["TInfluenza", "TEST", 141, 151], ["a nonspecific respiratory illness", "PROBLEM", 172, 205], ["fever", "PROBLEM", 217, 222], ["cough", "PROBLEM", 234, 239], ["pharyngitis", "PROBLEM", 247, 258], ["Disease Control", "TREATMENT", 290, 305], ["pharyngitis", "OBSERVATION", 247, 258]]], ["Laboratory diagnosis of ILI is typically performed by virus isolation in cell culture, antigen detection, and nucleic acid-amplification methods such as singleplex polymerase chain reaction (PCR).", [["cell", "ANATOMY", 73, 77], ["ILI", "DISEASE", 24, 27], ["cell", "CELL", 73, 77], ["ILI", "PROBLEM", 24, 27], ["virus isolation", "TEST", 54, 69], ["cell culture", "TEST", 73, 85], ["antigen detection", "TEST", 87, 104], ["nucleic acid-amplification methods", "PROBLEM", 110, 144], ["singleplex polymerase chain reaction", "PROBLEM", 153, 189], ["ILI", "OBSERVATION", 24, 27]]], ["Although multiplex nucleic acid-amplification systems for simultaneous detection of multiple respiratory pathogens have been described [1] [2] [3] [4] [5] , they are not yet widely implemented, primarily for reasons of complexity and cost.B R I E F R E P O R TWe recently described an inexpensive, sensitive, highly multiplexed system for differential diagnosis of infectious diseases [6] .", [["infectious diseases", "DISEASE", 365, 384], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 135, 154], ["multiplex nucleic acid-amplification systems", "PROBLEM", 9, 53], ["simultaneous detection", "TEST", 58, 80], ["multiple respiratory pathogens", "PROBLEM", 84, 114], ["infectious diseases", "PROBLEM", 365, 384], ["infectious", "OBSERVATION", 365, 375]]], ["MassTag PCR detected 22 different respiratory viral and bacterial pathogens in cultured isolates and respiratory specimens from infected individuals.", [["isolates", "ANATOMY", 88, 96], ["respiratory specimens", "ANATOMY", 101, 122], ["MassTag PCR", "TEST", 0, 11], ["different respiratory viral and bacterial pathogens", "PROBLEM", 24, 75], ["cultured isolates", "TEST", 79, 96], ["respiratory specimens", "TEST", 101, 122], ["infected individuals", "PROBLEM", 128, 148], ["22 different", "OBSERVATION_MODIFIER", 21, 33], ["respiratory viral", "OBSERVATION", 34, 51], ["bacterial pathogens", "OBSERVATION", 56, 75]]], ["MassTag PCR also detected the relevant pathogens in specimens from patients with Ebola, Marburg, Lassa, Rift Valley, and Crimean-Congo hemorrhagic fever [7] .B R I E F R E P O R TIn New York State (NYS) during winter 2004, there was a high incidence of ILI that tested negative both for influenza virus A (FLUAV) and B (FLUBV), by real-time reverse transcription (RT)-PCR, and for other respiratory viruses, by conventional virus culture.", [["specimens", "ANATOMY", 52, 61], ["Ebola, Marburg, Lassa, Rift Valley", "DISEASE", 81, 115], ["Crimean-Congo hemorrhagic fever", "DISEASE", 121, 152], ["ILI", "DISEASE", 253, 256], ["respiratory viruses", "DISEASE", 387, 406], ["specimens", "CANCER", 52, 61], ["patients", "ORGANISM", 67, 75], ["Ebola", "ORGANISM", 81, 86], ["influenza virus A", "ORGANISM", 287, 304], ["B (FLUBV", "ORGANISM", 317, 325], ["patients", "SPECIES", 67, 75], ["Congo hemorrhagic fever", "SPECIES", 129, 152], ["influenza virus", "SPECIES", 287, 302], ["Crimean-Congo hemorrhagic fever", "SPECIES", 121, 152], ["influenza virus A", "SPECIES", 287, 304], ["FLUAV", "SPECIES", 306, 311], ["FLUBV", "SPECIES", 320, 325], ["MassTag PCR", "TEST", 0, 11], ["Ebola", "PROBLEM", 81, 86], ["Congo hemorrhagic fever", "PROBLEM", 129, 152], ["ILI", "PROBLEM", 253, 256], ["influenza virus", "PROBLEM", 287, 302], ["PCR", "TEST", 368, 371], ["other respiratory viruses", "PROBLEM", 381, 406], ["conventional virus culture", "TEST", 411, 437], ["respiratory", "ANATOMY", 387, 398], ["viruses", "OBSERVATION", 399, 406]]], ["Concern that this finding reflected circulation of a novel pathogen led us to perform MassTag PCR analyses.B R I E F R E P O R TPatients, materials, and methods.", [["a novel pathogen", "PROBLEM", 51, 67], ["MassTag PCR analyses", "TEST", 86, 106], ["O R TPatients, materials", "TREATMENT", 123, 147]]], ["Patients with ILI were identified during visits to NYS health-care providers belonging to the CDC Influenza Sentinel Physicians Network during the 2004-2005 influenza season (from 1 October 2004 to 31 May 2005) .", [["ILI", "DISEASE", 14, 17], ["Influenza", "DISEASE", 98, 107], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ILI", "PROBLEM", 14, 17]]], ["Respiratory (oropharyngeal, nasopharyngeal, and nasal) swabs were transported in M4 medium (Remel).", [["Respiratory", "ANATOMY", 0, 11], ["oropharyngeal", "ANATOMY", 13, 26], ["nasopharyngeal", "ANATOMY", 28, 42], ["nasal", "ANATOMY", 48, 53], ["swabs", "ANATOMY", 55, 60], ["Respiratory (oropharyngeal, nasopharyngeal, and nasal) swabs", "DISEASE", 0, 60], ["oropharyngeal", "ORGANISM_SUBDIVISION", 13, 26], ["nasopharyngeal", "CANCER", 28, 42], ["nasal", "ORGANISM_SUBDIVISION", 48, 53], ["Respiratory (oropharyngeal, nasopharyngeal, and nasal) swabs", "PROBLEM", 0, 60], ["oropharyngeal", "ANATOMY", 13, 26], ["nasopharyngeal", "ANATOMY", 28, 42], ["nasal", "ANATOMY", 48, 53]]], ["The patients in this study were 4 months to 98 years old, with a median age of 25 years.B R I E F R E P O R TPenicillin, streptomycin, and mycostatin were added to specimens before the latter were inoculated into primary rhesusmonkey kidney (RhMK) cells for conventional virus culture.B R I E F R E P O R TIn addition, samples were tested for the presence of FLUAV or FLUBV, by either direct antigen detection (BD Directigen) or real-time RT-PCR assays.", [["specimens", "ANATOMY", 164, 173], ["primary rhesusmonkey kidney (RhMK) cells", "ANATOMY", 213, 253], ["samples", "ANATOMY", 319, 326], ["TPenicillin", "CHEMICAL", 108, 119], ["streptomycin", "CHEMICAL", 121, 133], ["mycostatin", "CHEMICAL", 139, 149], ["TPenicillin", "CHEMICAL", 108, 119], ["streptomycin", "CHEMICAL", 121, 133], ["mycostatin", "CHEMICAL", 139, 149], ["patients", "ORGANISM", 4, 12], ["O R TPenicillin", "SIMPLE_CHEMICAL", 104, 119], ["streptomycin", "SIMPLE_CHEMICAL", 121, 133], ["mycostatin", "SIMPLE_CHEMICAL", 139, 149], ["rhesusmonkey kidney (RhMK) cells", "CELL", 221, 253], ["FLUAV", "GENE_OR_GENE_PRODUCT", 359, 364], ["mycostatin", "DNA", 139, 149], ["primary rhesusmonkey kidney (RhMK) cells", "CELL_LINE", 213, 253], ["FLUAV", "PROTEIN", 359, 364], ["FLUBV", "PROTEIN", 368, 373], ["patients", "SPECIES", 4, 12], ["O R TPenicillin", "TREATMENT", 104, 119], ["streptomycin", "TREATMENT", 121, 133], ["mycostatin", "TREATMENT", 139, 149], ["conventional virus culture", "TEST", 258, 284], ["samples", "TEST", 319, 326], ["FLUAV", "PROBLEM", 359, 364], ["RT-PCR assays", "TEST", 439, 452], ["kidney", "ANATOMY", 234, 240]]], ["Primer and probe sequences were provided, by the CDC, to the Laboratory Response Network (http://www.bt.cdc.gov/lrn/).", [["Primer and probe sequences", "DNA", 0, 26], ["Primer and probe sequences", "TEST", 0, 26]]], ["For real-time RT-PCR, RNA was extracted from 140 mL of specimen, by use of viral-RNA kits (Qiagen), and was eluted into a 60-mL volume (Qiagen).", [["specimen", "ANATOMY", 55, 63], ["RNA", "TEST", 22, 25], ["viral-RNA kits", "TREATMENT", 75, 89]]], ["Inoculated RhMK cells were observed 3 times/week for 2 weeks, to determine cytopathic effect.", [["RhMK cells", "ANATOMY", 11, 21], ["RhMK cells", "CELL", 11, 21], ["RhMK cells", "CELL_LINE", 11, 21], ["Inoculated RhMK cells", "PROBLEM", 0, 21], ["cytopathic effect", "PROBLEM", 75, 92]]], ["Between days 7 and 10, cultures were tested for hemadsorption; positive cultures were assayed for influenza and parainfluenza viruses, by direct immunofluorescence assay (Chemicon).", [["influenza and parainfluenza viruses", "DISEASE", 98, 133], ["parainfluenza viruses", "ORGANISM", 112, 133], ["parainfluenza", "SPECIES", 112, 125], ["cultures", "TEST", 23, 31], ["hemadsorption", "PROBLEM", 48, 61], ["positive cultures", "PROBLEM", 63, 80], ["influenza", "PROBLEM", 98, 107], ["parainfluenza viruses", "PROBLEM", 112, 133], ["direct immunofluorescence assay", "TEST", 138, 169], ["parainfluenza viruses", "OBSERVATION", 112, 133]]], ["When cytopathic effect was observed in the absence of hemadsorption, immu- nofluorescence assay was used to test cells for adenovirus (Chemicon) and herpes simplex virus-1 and -2 (MicroTrack).", [["cells", "ANATOMY", 113, 118], ["cells", "CELL", 113, 118], ["adenovirus", "ORGANISM", 123, 133], ["Chemicon", "GENE_OR_GENE_PRODUCT", 135, 143], ["herpes simplex virus-1", "ORGANISM", 149, 171], ["-2", "GENE_OR_GENE_PRODUCT", 176, 178], ["immu", "PROTEIN", 69, 73], ["herpes simplex virus-1", "SPECIES", 149, 171], ["adenovirus", "SPECIES", 123, 133], ["herpes simplex virus-1", "SPECIES", 149, 171], ["cytopathic effect", "PROBLEM", 5, 22], ["hemadsorption", "TEST", 54, 67], ["immu- nofluorescence assay", "TEST", 69, 95], ["adenovirus", "PROBLEM", 123, 133], ["Chemicon", "TEST", 135, 143], ["herpes simplex virus", "TEST", 149, 169]]], ["Total nucleic acids, extracted from 250 mL of specimen by the NucliSens Magnetic Extraction Method, were eluted into a 50-mL volume (bioM\u00e9rieux).", [["specimen", "ANATOMY", 46, 54], ["nucleic acids", "CHEMICAL", 6, 19], ["Total nucleic acids", "TREATMENT", 0, 19], ["the NucliSens Magnetic Extraction Method", "TREATMENT", 58, 98], ["nucleic acids", "OBSERVATION", 6, 19]]], ["Before they were extracted, samples were spiked with a transcript encoding a portion of the green-fluorescent protein, to control for both extraction efficiency and the absence of RT-PCR inhibitors.", [["samples", "ANATOMY", 28, 35], ["green-fluorescent protein", "PROTEIN", 92, 117], ["the green-fluorescent protein", "TREATMENT", 88, 117], ["both extraction efficiency", "PROBLEM", 134, 160], ["RT-PCR inhibitors", "TREATMENT", 180, 197]]], ["The MassTag PCR assay targeted the following respiratory pathogens: FLUAV and FLUBV; human respiratory syncytial viruses A and B; human coronaviruses OC43, 229E, and SARS; human parainfluenza viruses 1-3 (HPIV-1, -2, and -3); human metapneumovirus (HMPV); human enterovirus (HEV); human adenovirus (HADV); Mycoplasma pneumoniae; Legionella pneumophila; Chlamydia pneumoniae; Streptococcus pneumoniae; Haemophi-lus influenzae; and Neisseria meningitidis [6] .", [["respiratory syncytial viruses", "DISEASE", 91, 120], ["SARS", "DISEASE", 166, 170], ["parainfluenza viruses", "DISEASE", 178, 199], ["human metapneumovirus", "DISEASE", 226, 247], ["human enterovirus (HEV)", "DISEASE", 256, 279], ["Mycoplasma pneumoniae", "DISEASE", 306, 327], ["Legionella pneumophila", "DISEASE", 329, 351], ["Chlamydia pneumoniae", "DISEASE", 353, 373], ["Streptococcus pneumoniae", "DISEASE", 375, 399], ["Neisseria meningitidis", "DISEASE", 430, 452], ["human respiratory syncytial viruses A", "ORGANISM", 85, 122], ["B", "GENE_OR_GENE_PRODUCT", 127, 128], ["human", "ORGANISM", 130, 135], ["coronaviruses OC43", "ORGANISM", 136, 154], ["229E", "GENE_OR_GENE_PRODUCT", 156, 160], ["human", "ORGANISM", 172, 177], ["parainfluenza viruses 1-3", "ORGANISM", 178, 203], ["HPIV-1", "ORGANISM", 205, 211], ["-2", "GENE_OR_GENE_PRODUCT", 213, 215], ["-3", "GENE_OR_GENE_PRODUCT", 221, 223], ["human", "ORGANISM", 226, 231], ["metapneumovirus", "ORGANISM", 232, 247], ["HMPV", "ORGANISM", 249, 253], ["human enterovirus", "ORGANISM", 256, 273], ["HEV", "ORGANISM", 275, 278], ["human adenovirus (HADV);", "ORGANISM", 281, 305], ["Mycoplasma pneumoniae", "ORGANISM", 306, 327], ["Legionella pneumophila", "ORGANISM", 329, 351], ["Chlamydia pneumoniae", "ORGANISM", 353, 373], ["Streptococcus pneumoniae", "ORGANISM", 375, 399], ["Haemophi-lus influenzae", "ORGANISM", 401, 424], ["Neisseria meningitidis", "ORGANISM", 430, 452], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 172, 177], ["parainfluenza viruses", "SPECIES", 178, 199], ["human", "SPECIES", 226, 231], ["metapneumovirus", "SPECIES", 232, 247], ["human", "SPECIES", 256, 261], ["enterovirus", "SPECIES", 262, 273], ["human", "SPECIES", 281, 286], ["Mycoplasma pneumoniae", "SPECIES", 306, 327], ["Legionella pneumophila", "SPECIES", 329, 351], ["Chlamydia pneumoniae", "SPECIES", 353, 373], ["Streptococcus pneumoniae", "SPECIES", 375, 399], ["Haemophi-lus influenzae", "SPECIES", 401, 424], ["Neisseria meningitidis", "SPECIES", 430, 452], ["human respiratory syncytial viruses A", "SPECIES", 85, 122], ["human coronaviruses OC43", "SPECIES", 130, 154], ["human parainfluenza viruses", "SPECIES", 172, 199], ["human metapneumovirus", "SPECIES", 226, 247], ["HMPV", "SPECIES", 249, 253], ["human enterovirus", "SPECIES", 256, 273], ["HEV", "SPECIES", 275, 278], ["human adenovirus", "SPECIES", 281, 297], ["HADV", "SPECIES", 299, 303], ["Mycoplasma pneumoniae", "SPECIES", 306, 327], ["Legionella pneumophila", "SPECIES", 329, 351], ["Chlamydia pneumoniae", "SPECIES", 353, 373], ["Streptococcus pneumoniae", "SPECIES", 375, 399], ["Haemophi-lus influenzae", "SPECIES", 401, 424], ["Neisseria meningitidis", "SPECIES", 430, 452], ["The MassTag PCR assay", "TEST", 0, 21], ["FLUAV", "TEST", 68, 73], ["FLUBV", "TEST", 78, 83], ["human respiratory syncytial viruses", "PROBLEM", 85, 120], ["human coronaviruses OC43", "TEST", 130, 154], ["SARS", "TEST", 166, 170], ["human parainfluenza viruses", "TEST", 172, 199], ["HPIV", "TEST", 205, 209], ["human metapneumovirus (HMPV", "PROBLEM", 226, 253], ["human enterovirus", "PROBLEM", 256, 273], ["human adenovirus (HADV", "PROBLEM", 281, 303], ["Mycoplasma pneumoniae", "PROBLEM", 306, 327], ["Legionella pneumophila", "PROBLEM", 329, 351], ["Chlamydia pneumoniae", "PROBLEM", 353, 373], ["Streptococcus pneumoniae", "PROBLEM", 375, 399], ["Haemophi", "PROBLEM", 401, 409], ["lus influenzae", "PROBLEM", 410, 424], ["Neisseria meningitidis", "PROBLEM", 430, 452], ["respiratory syncytial viruses", "OBSERVATION", 91, 120]]], ["A primer pair targeting the green-fluorescent-protein quality-control sequence was also included.", [["primer pair", "DNA", 2, 13], ["green-fluorescent-protein quality-control sequence", "DNA", 28, 78], ["A primer pair", "TEST", 0, 13]]], ["MassTag PCR-amplification products were analyzed in a single-quadrapole mass spectrometer using positive-mode atmospheric-pressure chemical ionization (Agilent Technologies).B R I E F R E P O R TSamples that, in MassTag PCR, tested positive for M. pneumoniae, L. pneumophila, C. pneumoniae, N. meningitidis, HEV, and HADV were also tested for these pathogens by real-time PCR assays that the NYS Department of Health Clinical Laboratory Evaluation Program had approved for clinical use.", [["M. pneumoniae", "ORGANISM", 245, 258], ["L. pneumophila", "ORGANISM", 260, 274], ["C. pneumoniae", "ORGANISM", 276, 289], ["N. meningitidis", "ORGANISM", 291, 306], ["HEV", "ORGANISM", 308, 311], ["HADV", "GENE_OR_GENE_PRODUCT", 317, 321], ["M. pneumoniae", "SPECIES", 245, 258], ["L. pneumophila", "SPECIES", 260, 274], ["C. pneumoniae", "SPECIES", 276, 289], ["N. meningitidis", "SPECIES", 291, 306], ["M. pneumoniae", "SPECIES", 245, 258], ["L. pneumophila", "SPECIES", 260, 274], ["C. pneumoniae", "SPECIES", 276, 289], ["N. meningitidis", "SPECIES", 291, 306], ["HEV", "SPECIES", 308, 311], ["HADV", "SPECIES", 317, 321], ["MassTag PCR", "TEST", 0, 11], ["amplification products", "TREATMENT", 12, 34], ["B R I E F R E P O R TSamples", "TEST", 174, 202], ["MassTag PCR", "TEST", 212, 223], ["M. pneumoniae", "PROBLEM", 245, 258], ["L. pneumophila", "PROBLEM", 260, 274], ["C. pneumoniae", "PROBLEM", 276, 289], ["N. meningitidis", "PROBLEM", 291, 306], ["HEV", "PROBLEM", 308, 311], ["HADV", "PROBLEM", 317, 321], ["these pathogens", "PROBLEM", 343, 358], ["pneumoniae", "OBSERVATION", 248, 258], ["L.", "OBSERVATION_MODIFIER", 260, 262], ["pneumophila", "OBSERVATION", 263, 274], ["pneumoniae", "OBSERVATION", 279, 289], ["meningitidis", "OBSERVATION", 294, 306]]], ["Published PCR assays were used for samples positive for human coronaviruses OC43 and 229E [8] , H. influenzae (types b and c [9] ), and S. pneumoniae (serotypes 1, 3, 5-7, 9, 14, 19, 22, 23, 29, and 46 [10] ).", [["samples", "ANATOMY", 35, 42], ["human", "ORGANISM", 56, 61], ["coronaviruses", "ORGANISM", 62, 75], ["OC43", "GENE_OR_GENE_PRODUCT", 76, 80], ["229E [8", "ORGANISM", 85, 92], ["H. influenzae", "ORGANISM", 96, 109], ["c [9", "ORGANISM", 123, 127], ["S. pneumoniae", "ORGANISM", 136, 149], ["human", "SPECIES", 56, 61], ["H. influenzae", "SPECIES", 96, 109], ["S. pneumoniae", "SPECIES", 136, 149], ["human coronaviruses", "SPECIES", 56, 75], ["H. influenzae", "SPECIES", 96, 109], ["S. pneumoniae", "SPECIES", 136, 149], ["Published PCR assays", "TEST", 0, 20], ["samples", "TEST", 35, 42], ["human coronaviruses OC43", "TEST", 56, 80], ["H. influenzae", "TEST", 96, 109], ["types b", "TEST", 111, 118], ["c", "TEST", 123, 124], ["S. pneumoniae", "PROBLEM", 136, 149], ["serotypes", "TEST", 151, 160], ["pneumoniae", "OBSERVATION", 139, 149]]], ["The VP4 and VP1 gene regions of pi-cornaviruses were amplified as described elsewhere [2, 11] .", [["VP4", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP1", "GENE_OR_GENE_PRODUCT", 12, 15], ["pi-cornaviruses", "GENE_OR_GENE_PRODUCT", 32, 47], ["VP4 and VP1 gene regions", "DNA", 4, 28], ["The VP4 and VP1 gene regions of pi-cornaviruses", "PROBLEM", 0, 47], ["VP1", "ANATOMY_MODIFIER", 12, 15]]], ["MassTag PCR-amplification products other than those for influenza viruses were cloned into pGEM-Teasy plasmid vectors (Promega) and were sequenced by dideoxy sequencing on an ABI 310 Genetic Analyzer Sequence Analyzer (Applied Biosystems).", [["Promega", "ORGANISM", 119, 126], ["pGEM-Teasy plasmid vectors", "DNA", 91, 117], ["MassTag PCR", "TEST", 0, 11], ["amplification products", "TREATMENT", 12, 34], ["influenza viruses", "PROBLEM", 56, 73], ["Teasy plasmid vectors", "TREATMENT", 96, 117], ["an ABI", "TEST", 172, 178], ["Genetic Analyzer Sequence Analyzer", "TEST", 183, 217]]], ["Sequences were analyzed by use of the Wisconsin GCG software package (Accelrys) and MEGA 3.1 (http://www .megasoftware.net/).B R I E F R E P O R TResults.", [["MEGA", "TEST", 84, 88]]], ["During the 2004-2005 influenza season, the NYS Department of Health received 166 samples through the Influenza Sentinel Physicians Surveillance Network, 151 of which were included in the present study.", [["influenza", "DISEASE", 21, 30], ["the present study", "TEST", 183, 200]]], ["Samples were analyzed on arrival in the laboratory, by antigen-detection and real-time RT-PCR assays designed to identify influenza viruses, as well as by conventional virus culture to detect additional respiratory-viral pathogens.", [["Samples", "ANATOMY", 0, 7], ["influenza viruses", "DISEASE", 122, 139], ["respiratory-viral pathogens", "DISEASE", 203, 230], ["Samples", "TEST", 0, 7], ["RT-PCR assays", "TEST", 87, 100], ["influenza viruses", "PROBLEM", 122, 139], ["conventional virus culture", "TEST", 155, 181], ["additional respiratory-viral pathogens", "PROBLEM", 192, 230], ["respiratory", "ANATOMY", 203, 214], ["viral pathogens", "OBSERVATION", 215, 230]]], ["FLUAV ( ) and FLUBV ( ) n p 58 n p 10 accounted for the majority of the identified pathogens; in addition, HADV ( ), HPIV-1 ( ), and herpes simplex n p 2 n p 1 viruses ( ) were isolated.", [["herpes simplex", "DISEASE", 133, 147], ["FLUAV", "GENE_OR_GENE_PRODUCT", 0, 5], ["HADV", "GENE_OR_GENE_PRODUCT", 107, 111], ["HPIV-1", "ORGANISM", 117, 123], ["herpes simplex n p 2 n p 1 viruses", "ORGANISM", 133, 167], ["FLUAV", "PROTEIN", 0, 5], ["herpes simplex", "SPECIES", 133, 147], ["HADV", "SPECIES", 107, 111], ["HPIV-1", "SPECIES", 117, 123], ["herpes simplex n p 2 n p 1 viruses", "SPECIES", 133, 167], ["FLUBV", "TEST", 14, 19], ["p", "TEST", 26, 27], ["the identified pathogens", "PROBLEM", 68, 92], ["HADV", "TEST", 107, 111], ["HPIV", "TEST", 117, 121], ["herpes simplex", "PROBLEM", 133, 147], ["pathogens", "OBSERVATION", 83, 92]]], ["In 1 of the samples, coinfection n p 2 with FLUAV and FLUBV was present.", [["samples", "ANATOMY", 12, 19], ["coinfection", "DISEASE", 21, 32], ["FLUAV", "CANCER", 44, 49], ["FLUBV", "CANCER", 54, 59], ["coinfection", "PROBLEM", 21, 32], ["FLUAV", "TREATMENT", 44, 49], ["FLUBV", "TREATMENT", 54, 59], ["coinfection", "OBSERVATION", 21, 32]]], ["In summary, the analyses identified 73 pathogens in 72 samples, providing a presumptive diagnosis in 48% of cases.", [["samples", "ANATOMY", 55, 62], ["the analyses", "TEST", 12, 24]]], ["However, no pathogen was identified in 79 samples.", [["samples", "ANATOMY", 42, 49], ["pathogen", "PROBLEM", 12, 20], ["no", "UNCERTAINTY", 9, 11], ["pathogen", "OBSERVATION", 12, 20]]], ["Because some samples were collected 110 days after the onset of symptoms, low microbial load at the time of collection could have accounted for some of the negative results.", [["samples", "ANATOMY", 13, 20], ["samples", "CANCER", 13, 20], ["symptoms", "PROBLEM", 64, 72], ["low microbial load", "PROBLEM", 74, 92], ["collection", "PROBLEM", 108, 118], ["low microbial", "OBSERVATION_MODIFIER", 74, 87]]], ["However, many of these pathogen-negative samples were clustered within the 8-week period between October and December 2004 and were compatible with the presence of an unidentified pathogen.", [["samples", "ANATOMY", 41, 48], ["samples", "CANCER", 41, 48], ["these pathogen", "TEST", 17, 31], ["an unidentified pathogen", "PROBLEM", 164, 188], ["pathogen", "OBSERVATION", 180, 188]]], ["We therefore retrospectively investigated all available stored specimens, using multiplex MassTag PCR.B R I E F R E P O R TAnalysis of the retrospective samples by MassTag PCR indicated the presence of 109 pathogens in 93 samples and identified a pathogen in 33% of the previously negative specimens (table 1, top).", [["specimens", "ANATOMY", 63, 72], ["samples", "ANATOMY", 153, 160], ["samples", "ANATOMY", 222, 229], ["specimens", "ANATOMY", 290, 299], ["samples", "CANCER", 222, 229], ["multiplex MassTag PCR", "TEST", 80, 101], ["the retrospective samples", "TEST", 135, 160], ["MassTag PCR", "TEST", 164, 175], ["109 pathogens in 93 samples", "PROBLEM", 202, 229], ["a pathogen", "TEST", 245, 255]]], ["In the 26 cases that had not been diagnosed previously, 33 pathogens were detected.", [["33 pathogens", "PROBLEM", 56, 68]]], ["In 8 of the samples for which a pathogen had been identified previously, MassTag PCR revealed the presence of a total of 9 additional pathogens (table 1, bottom) and, furthermore, revealed infection with 2 pathogens in each of 9 patients and with 3 pathogens in each of 4 patients.B R I E F R E P O R TFor HADV, HPIV-1, and FLUBV, the results of the MassTag PCR assay were 100% concordant with those of the real-time RT-PCR assay; for FLUAV, they were 96% concordant.", [["samples", "ANATOMY", 12, 19], ["infection", "DISEASE", 189, 198], ["samples", "CANCER", 12, 19], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 272, 280], ["HPIV-1", "GENE_OR_GENE_PRODUCT", 312, 318], ["MassTag PCR", "DNA", 73, 84], ["HADV", "DNA", 306, 310], ["HPIV", "DNA", 312, 316], ["FLUBV", "DNA", 324, 329], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 272, 280], ["a pathogen", "PROBLEM", 30, 40], ["MassTag PCR", "TEST", 73, 84], ["9 additional pathogens", "PROBLEM", 121, 143], ["infection", "PROBLEM", 189, 198], ["2 pathogens", "PROBLEM", 204, 215], ["3 pathogens", "PROBLEM", 247, 258], ["B R I E F R E P O R TFor HADV", "TEST", 281, 310], ["HPIV", "TEST", 312, 316], ["FLUBV", "TEST", 324, 329], ["the MassTag PCR assay", "TEST", 346, 367], ["FLUAV", "TEST", 435, 440], ["infection", "OBSERVATION", 189, 198]]], ["Results were discordant for 2 FLUAV samples that real-time RT-PCR had found to be positive; the viral load in these samples, as indicated by the real-time RT-PCR cycle-threshold values (data not shown), was !1000 RNA copies/reaction, which is below the MassTag PCR assay's limit of detection for FLUAV [6] .B R I E F R E P O R TThe degenerate HEV primers used in the MassTag PCR assay target conserved regions of the 5 untranslated region (5 -UTR) of picornaviruses, regions that are also present in human rhinoviruses (HRV).", [["samples", "ANATOMY", 116, 123], ["HEV", "ORGANISM", 343, 346], ["human", "ORGANISM", 500, 505], ["rhinoviruses", "ORGANISM", 506, 518], ["5 untranslated region", "DNA", 417, 438], ["5 -UTR", "DNA", 440, 446], ["human", "SPECIES", 500, 505], ["HEV", "SPECIES", 343, 346], ["human rhinoviruses", "SPECIES", 500, 518], ["2 FLUAV samples", "TEST", 28, 43], ["RT-PCR", "TEST", 59, 65], ["the viral load", "TEST", 92, 106], ["these samples", "TEST", 110, 123], ["PCR cycle", "TEST", 158, 167], ["threshold values", "TEST", 168, 184], ["RNA copies/reaction", "TEST", 213, 232], ["detection", "TEST", 282, 291], ["FLUAV", "TEST", 296, 301], ["TThe degenerate HEV primers", "TEST", 327, 354], ["the MassTag PCR", "TEST", 363, 378], ["picornaviruses", "PROBLEM", 451, 465], ["positive", "OBSERVATION", 82, 90], ["viral load", "OBSERVATION", 96, 106], ["picornaviruses", "OBSERVATION", 451, 465]]], ["When samples that were found to be positive when tested by this primer pair were tested by a specific diagnostic real-time RT-PCR assay for HEV, 17 of the 18 cases yielded a negative result.", [["samples", "ANATOMY", 5, 12], ["samples", "CANCER", 5, 12], ["HEV", "ORGANISM", 140, 143], ["primer pair", "DNA", 64, 75], ["HEV", "SPECIES", 140, 143], ["HEV", "TEST", 140, 143]]], ["Reasoning that the products represented novel isolates of either HEV or HRV, we cloned all MassTag PCRamplification products.", [["HEV", "ORGANISM", 65, 68], ["MassTag PCRamplification products", "PROTEIN", 91, 124], ["HEV", "SPECIES", 65, 68], ["HEV", "PROBLEM", 65, 68], ["HRV", "PROBLEM", 72, 75], ["all MassTag PCRamplification products", "TREATMENT", 87, 124]]], ["Sequence analysis identified 2 HEVs and 16 HRVs (table 1) ; the 16 HRV sequences were most closely related to a mixed population of HEV and HRV 5 -UTRs that, in the GenBank database, are listed as \"Antwerp rhinovirus\" [12] .", [["HEVs", "ANATOMY", 31, 35], ["HEV", "ORGANISM", 132, 135], ["HRVs", "DNA", 43, 47], ["16 HRV sequences", "DNA", 64, 80], ["HEV and HRV 5 -UTRs", "DNA", 132, 151], ["HEV", "SPECIES", 132, 135], ["Antwerp rhinovirus", "SPECIES", 198, 216], ["Sequence analysis", "TEST", 0, 17], ["HEVs", "TEST", 31, 35], ["16 HRVs", "TEST", 40, 47], ["the 16 HRV sequences", "TEST", 60, 80]]], ["However, because short 5 -UTR sequences are not suitable for assignment of phylogenetic relationships, we obtained additional sequences, using degenerate primer sets targeting the VP4 gene region [2] .", [["VP4", "GENE_OR_GENE_PRODUCT", 180, 183], ["short 5 -UTR sequences", "DNA", 17, 39], ["VP4 gene region", "DNA", 180, 195], ["short 5 -UTR sequences", "TEST", 17, 39], ["additional sequences", "TEST", 115, 135], ["degenerate primer sets", "TREATMENT", 143, 165]]], ["Phylogenetic analysis of these VP4 sequences indicated that HRV group A was present in 2 cases and that HRV group B was present in 3 cases (table 1); in 3 instances, the sample was exhausted before an amplification product was obtained.", [["sample", "ANATOMY", 170, 176], ["VP4", "GENE_OR_GENE_PRODUCT", 31, 34], ["VP4 sequences", "DNA", 31, 44], ["Phylogenetic analysis", "TEST", 0, 21], ["these VP4 sequences", "TEST", 25, 44]]], ["For the 8 remaining HRV cases, the sequences clustered in a clade at the root of HRV group A, distinct from the described group A or group B serotypes [13] (figure 1).", [["root", "ANATOMY", 73, 77], ["the sequences", "TEST", 31, 44], ["group B serotypes", "PROBLEM", 133, 150]]], ["In 1 case (specimen 074), additional analysis, using a highly degenerate primer set [11] , allowed amplification of a partial VP1 sequence; the analysis supported the phylogenetic position indicated by analysis of VP4 (data not shown).B R I E F R E P O R TDiscussion.", [["VP4", "GENE_OR_GENE_PRODUCT", 214, 217], ["VP1 sequence", "DNA", 126, 138], ["VP4", "PROTEIN", 214, 217], ["additional analysis", "TEST", 26, 45], ["a partial VP1 sequence", "TEST", 116, 138], ["the analysis", "TEST", 140, 152], ["VP4 (data", "TEST", 214, 223]]], ["ILI is a significant cause of morbidity and mortality in the United States, accounting annually for \u223c36,000 deaths, \u223c150,000 hospitalizations, and up to $12 billion in direct and indirect costs [14] .", [["ILI", "DISEASE", 0, 3], ["deaths", "DISEASE", 108, 114], ["ILI", "PROBLEM", 0, 3], ["morbidity", "PROBLEM", 30, 39], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["morbidity", "OBSERVATION", 30, 39]]], ["The advent of sensitive, affordable methods for differential diagnosis of the infectious pathogens that can cause ILI has the potential to reduce the economic burden afforded by these pathogens and to improve clinical outcomes by facilitating early selection of appropriate antimicrobials.", [["ILI", "DISEASE", 114, 117], ["the infectious pathogens", "PROBLEM", 74, 98], ["ILI", "PROBLEM", 114, 117], ["the economic burden", "PROBLEM", 146, 165], ["these pathogens", "PROBLEM", 178, 193], ["appropriate antimicrobials", "TREATMENT", 262, 288], ["infectious", "OBSERVATION", 78, 88]]], ["The importance of developing strategies for triage of patients with acute respiratory infection to specific treatment regimens is underscored in the context of pandemic-influenza preparedness and the limited supply of influenza antiviral drugs.B R I E F R E P O R TThe present study was undertaken to investigate the causes of ILI in NYS during the period from 1 October 2004 to 31 May 2005.", [["respiratory", "ANATOMY", 74, 85], ["acute respiratory infection", "DISEASE", 68, 95], ["influenza", "DISEASE", 169, 178], ["ILI", "DISEASE", 327, 330], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["triage", "TEST", 44, 50], ["acute respiratory infection", "PROBLEM", 68, 95], ["specific treatment regimens", "TREATMENT", 99, 126], ["pandemic", "PROBLEM", 160, 168], ["influenza preparedness", "PROBLEM", 169, 191], ["influenza antiviral drugs", "TREATMENT", 218, 243], ["TThe present study", "TEST", 264, 282], ["ILI", "PROBLEM", 327, 330], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory", "ANATOMY", 74, 85], ["infection", "OBSERVATION", 86, 95], ["influenza", "OBSERVATION", 169, 178], ["ILI", "OBSERVATION", 327, 330]]], ["Clinical samples obtained by physicians in a surveillance network were submitted for analysis by a standard diagnostic protocol using virus culture, antigen detection, and molecular assays.", [["samples", "ANATOMY", 9, 16], ["a surveillance network", "TEST", 43, 65], ["virus culture", "TEST", 134, 147], ["antigen detection", "TEST", 149, 166], ["molecular assays", "TEST", 172, 188]]], ["In addition to the pathogens identified by these methods, MassTag PCR detected HRV, HEV, S. pneumoniae, M. pneumoniae, H. influenzae, HMPV, human coronavirus OC43, human respiratory syncytial virus A, HPIV-1, and N. meningitidis infections.", [["respiratory syncytial virus", "DISEASE", 170, 197], ["N. meningitidis infections", "DISEASE", 213, 239], ["HEV", "ORGANISM", 84, 87], ["S. pneumoniae", "ORGANISM", 89, 102], ["M. pneumoniae", "ORGANISM", 104, 117], ["H. influenzae", "ORGANISM", 119, 132], ["HMPV", "ORGANISM", 134, 138], ["human", "ORGANISM", 140, 145], ["coronavirus OC43", "ORGANISM", 146, 162], ["human respiratory syncytial virus A", "ORGANISM", 164, 199], ["HPIV-1", "ORGANISM", 201, 207], ["N. meningitidis", "ORGANISM", 213, 228], ["S. pneumoniae", "SPECIES", 89, 102], ["M. pneumoniae", "SPECIES", 104, 117], ["H. influenzae", "SPECIES", 119, 132], ["human", "SPECIES", 140, 145], ["coronavirus", "SPECIES", 146, 157], ["human", "SPECIES", 164, 169], ["respiratory syncytial virus", "SPECIES", 170, 197], ["HPIV-1", "SPECIES", 201, 207], ["N. meningitidis", "SPECIES", 213, 228], ["HRV", "SPECIES", 79, 82], ["HEV", "SPECIES", 84, 87], ["S. pneumoniae", "SPECIES", 89, 102], ["M. pneumoniae", "SPECIES", 104, 117], ["H. influenzae", "SPECIES", 119, 132], ["HMPV", "SPECIES", 134, 138], ["human coronavirus", "SPECIES", 140, 157], ["human respiratory syncytial virus A", "SPECIES", 164, 199], ["HPIV-1", "SPECIES", 201, 207], ["N. meningitidis", "SPECIES", 213, 228], ["the pathogens", "PROBLEM", 15, 28], ["these methods", "TEST", 43, 56], ["MassTag PCR", "TEST", 58, 69], ["HRV", "PROBLEM", 79, 82], ["HEV", "PROBLEM", 84, 87], ["S. pneumoniae", "PROBLEM", 89, 102], ["M. pneumoniae", "PROBLEM", 104, 117], ["H. influenzae", "PROBLEM", 119, 132], ["HMPV", "PROBLEM", 134, 138], ["human coronavirus OC43", "PROBLEM", 140, 162], ["human respiratory syncytial virus", "PROBLEM", 164, 197], ["HPIV", "TEST", 201, 205], ["N. meningitidis infections", "PROBLEM", 213, 239], ["pneumoniae", "OBSERVATION", 92, 102], ["pneumoniae", "OBSERVATION", 107, 117], ["syncytial virus", "OBSERVATION", 182, 197], ["meningitidis infections", "OBSERVATION", 216, 239]]], ["MassTag PCR also revealed instances in which virus-infected patients with ILI were coinfected with potentially treatable bacterial pathogens.B R I E F R E P O R TAn unexpected finding was the high incidence of rhinovirus infection.", [["ILI", "DISEASE", 74, 77], ["rhinovirus infection", "DISEASE", 210, 230], ["patients", "ORGANISM", 60, 68], ["rhinovirus", "ORGANISM", 210, 220], ["patients", "SPECIES", 60, 68], ["MassTag PCR", "TEST", 0, 11], ["instances in which virus", "PROBLEM", 26, 50], ["ILI", "PROBLEM", 74, 77], ["treatable bacterial pathogens", "PROBLEM", 111, 140], ["rhinovirus infection", "PROBLEM", 210, 230], ["infected", "OBSERVATION_MODIFIER", 51, 59], ["bacterial", "OBSERVATION_MODIFIER", 121, 130], ["pathogens", "OBSERVATION", 131, 140], ["high", "OBSERVATION_MODIFIER", 192, 196], ["rhinovirus", "OBSERVATION_MODIFIER", 210, 220], ["infection", "OBSERVATION", 221, 230]]], ["Although rhinoviruses are most commonly associated with mild upper-respiratory-tract disease, they have also been described in association with severe acute and lower-respiratory-tract infections in children, the elderly, and immunosup-pressed patients.", [["upper-respiratory-tract", "ANATOMY", 61, 84], ["rhinoviruses", "DISEASE", 9, 21], ["upper-respiratory-tract disease", "DISEASE", 61, 92], ["lower-respiratory-tract infections", "DISEASE", 161, 195], ["rhinoviruses", "ORGANISM", 9, 21], ["tract", "ORGANISM_SUBDIVISION", 79, 84], ["tract", "ORGANISM_SUBDIVISION", 179, 184], ["children", "ORGANISM", 199, 207], ["patients", "ORGANISM", 244, 252], ["children", "SPECIES", 199, 207], ["patients", "SPECIES", 244, 252], ["rhinoviruses", "PROBLEM", 9, 21], ["mild upper-respiratory-tract disease", "PROBLEM", 56, 92], ["severe acute and lower-respiratory-tract infections", "PROBLEM", 144, 195], ["rhinoviruses", "OBSERVATION", 9, 21], ["mild", "OBSERVATION_MODIFIER", 56, 60], ["tract disease", "OBSERVATION", 79, 92], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["lower", "OBSERVATION_MODIFIER", 161, 166], ["respiratory", "ANATOMY", 167, 178], ["tract infections", "OBSERVATION", 179, 195]]], ["In the present study we identified a new rhinovirus genotype in 8 cases of ILI that were clustered within an 8-week period from October to December 2004; thus, it appears that rhinoviruses were a major cause of ILI in our patient population during that period.B R I E F R E P O R TIn vitro evidence indicates that HRV infection may enhance the probability of streptococcal infection, through up-regulation of the platelet-activating-factor receptor [15] .", [["ILI", "DISEASE", 75, 78], ["rhinoviruses", "DISEASE", 176, 188], ["ILI", "DISEASE", 211, 214], ["HRV infection", "DISEASE", 314, 327], ["streptococcal infection", "DISEASE", 359, 382], ["rhinovirus", "ORGANISM", 41, 51], ["rhinoviruses", "ORGANISM", 176, 188], ["patient", "ORGANISM", 222, 229], ["platelet-activating-factor receptor", "GENE_OR_GENE_PRODUCT", 413, 448], ["platelet-activating-factor receptor", "PROTEIN", 413, 448], ["patient", "SPECIES", 222, 229], ["a new rhinovirus genotype", "PROBLEM", 35, 60], ["ILI", "PROBLEM", 75, 78], ["rhinoviruses", "PROBLEM", 176, 188], ["ILI", "PROBLEM", 211, 214], ["R TIn vitro", "TREATMENT", 278, 289], ["HRV infection", "PROBLEM", 314, 327], ["streptococcal infection", "PROBLEM", 359, 382], ["the platelet", "TEST", 409, 421], ["new", "OBSERVATION_MODIFIER", 37, 40], ["rhinovirus", "OBSERVATION", 41, 51], ["rhinoviruses", "OBSERVATION", 176, 188], ["infection", "OBSERVATION", 318, 327], ["streptococcal", "OBSERVATION_MODIFIER", 359, 372], ["infection", "OBSERVATION", 373, 382]]], ["Whether the 3 cases of coinfection by HRV and S. pneumoniae that were observed in the present study reflect a similar interaction between these 2 pathogens remains to be determined.", [["coinfection", "DISEASE", 23, 34], ["S. pneumoniae", "ORGANISM", 46, 59], ["S. pneumoniae", "SPECIES", 46, 59], ["S. pneumoniae", "SPECIES", 46, 59], ["coinfection", "PROBLEM", 23, 34], ["HRV", "PROBLEM", 38, 41], ["S. pneumoniae", "PROBLEM", 46, 59], ["these 2 pathogens", "PROBLEM", 138, 155], ["coinfection", "OBSERVATION", 23, 34], ["pneumoniae", "OBSERVATION", 49, 59]]], ["More comprehensive data are required before the role that multiple infections play in the pathogenesis of respiratory (or other) diseases can be assessed.B R I E F R E P O R TThe objective of MassTag PCR is to ensure comprehensive screening for the presence of a large number of identical as well as related genetic targets.", [["respiratory", "ANATOMY", 106, 117], ["infections", "DISEASE", 67, 77], ["respiratory (or other) diseases", "DISEASE", 106, 137], ["MassTag PCR", "DNA", 192, 203], ["multiple infections", "PROBLEM", 58, 77], ["respiratory (or other) diseases", "PROBLEM", 106, 137], ["MassTag PCR", "TEST", 192, 203], ["comprehensive screening", "TEST", 217, 240], ["multiple", "OBSERVATION_MODIFIER", 58, 66], ["infections", "OBSERVATION", 67, 77], ["respiratory", "ANATOMY", 106, 117], ["large", "OBSERVATION_MODIFIER", 263, 268]]], ["Thus, although the sensitivity is similar to that obtained with real-time PCR (10-50 molecules) when primers and targets are precisely complementary, we accept primers that are optimized to perform at a detection threshold of 500-1000 RNA molecules in highly multiplexed assay panels.", [["the sensitivity", "TEST", 15, 30], ["PCR", "TEST", 74, 77], ["multiplexed assay panels", "TEST", 259, 283]]], ["The advantage of such primer panels is underscored by the observation that they identified pathogens in previously negative samples and detected novel rhinovirus sequences that did not contribute to original primer design.", [["samples", "ANATOMY", 124, 131], ["rhinovirus", "ORGANISM", 151, 161], ["rhinovirus sequences", "DNA", 151, 171], ["such primer panels", "TEST", 17, 35], ["pathogens", "PROBLEM", 91, 100], ["novel rhinovirus sequences", "PROBLEM", 145, 171]]], ["Although the setup costs for MassTag PCR instrumentation are currently higher than those for real-time PCR (\u223c$80,000-$120,000 vs. \u223c$30,000-$100,000), MassTag PCR compares favorably with other systems.", [["the setup costs", "TREATMENT", 9, 24], ["MassTag PCR instrumentation", "TREATMENT", 29, 56], ["PCR", "TEST", 103, 106], ["MassTag PCR", "TEST", 150, 161]]], ["Virus culture for differential diagnosis of ILI takes up to 2 weeks and incurs materials and reagent costs of \u223c$50.", [["ILI", "DISEASE", 44, 47], ["Virus", "ORGANISM", 0, 5], ["Virus culture", "TEST", 0, 13], ["ILI", "PROBLEM", 44, 47]]], ["Alternative, rapid antigen-detection tests can be performed within 15-30 min, with reagent costs of $25, but have only 50%-90% of the sensitivity of virus culture.", [["rapid antigen-detection tests", "TEST", 13, 42], ["virus culture", "TEST", 149, 162]]], ["Realtime PCR assays are generally more sensitive than virus culture, can be performed in 4-6 h, and entail reagent costs of $30 per target; in contrast, MassTag PCR requires 6-8 h, costs $12 per sample, and allows investigation of 20 candidate viral and bacterial pathogens in a single reaction.B R I E F R E P O R TThe present study confirms the utility of MassTag PCR as a tool for surveillance, detection of outbreaks, and epidemiology.", [["Realtime PCR assays", "TEST", 0, 19], ["virus culture", "TEST", 54, 67], ["MassTag PCR", "TEST", 153, 164], ["viral and bacterial pathogens", "PROBLEM", 244, 273], ["a single reaction", "PROBLEM", 277, 294], ["TThe present study", "TEST", 315, 333], ["MassTag PCR", "PROBLEM", 358, 369], ["surveillance", "TEST", 384, 396], ["outbreaks", "PROBLEM", 411, 420]]], ["Its potential to rapidly analyze samples for the presence of a wide range of candidate viral and bacterial pathogens that may act alone or in concert suggests that it may also have applications in clinical medicine.", [["samples", "ANATOMY", 33, 40], ["viral and bacterial pathogens", "PROBLEM", 87, 116], ["clinical medicine", "TREATMENT", 197, 214]]]], "ba908985b472c0dc96fc9305642028b45e54cc44": [["Histology and immunofluorescenceOrgans were removed and fixed in 10% formaldehyde saline.", [["formaldehyde", "CHEMICAL", 69, 81], ["formaldehyde", "CHEMICAL", 69, 81], ["formaldehyde", "SIMPLE_CHEMICAL", 69, 81], ["saline", "SIMPLE_CHEMICAL", 82, 88], ["Histology", "TEST", 0, 9], ["immunofluorescenceOrgans", "TEST", 14, 38], ["10% formaldehyde saline", "TREATMENT", 65, 88]]], ["Tissues were embedded in paraffin, and for each mouse, three 5-\u00b5m sections are cut, at two levels separated by 100 \u00b5m, and stained with periodic acid-Schiff (PAS) or Hematoxylin Eosin (H&E).", [["Tissues", "ANATOMY", 0, 7], ["sections", "ANATOMY", 66, 74], ["acid-Schiff", "CHEMICAL", 145, 156], ["paraffin", "CHEMICAL", 25, 33], ["acid-Schiff", "CHEMICAL", 145, 156], ["Hematoxylin", "CHEMICAL", 166, 177], ["Eosin", "CHEMICAL", 178, 183], ["Tissues", "CANCER", 0, 7], ["mouse", "ORGANISM", 48, 53], ["\u00b5m sections", "MULTI-TISSUE_STRUCTURE", 63, 74], ["acid-Schiff", "SIMPLE_CHEMICAL", 145, 156], ["PAS", "SIMPLE_CHEMICAL", 158, 161], ["Hematoxylin Eosin", "SIMPLE_CHEMICAL", 166, 183], ["mouse", "SPECIES", 48, 53], ["mouse", "SPECIES", 48, 53], ["periodic acid-Schiff (PAS", "TREATMENT", 136, 161], ["Hematoxylin Eosin", "TREATMENT", 166, 183], ["acid-Schiff", "OBSERVATION", 145, 156]]], ["All histology sections were examined in a blinded fashion by two observers independently.", [["histology sections", "ANATOMY", 4, 22], ["histology sections", "CANCER", 4, 22], ["All histology sections", "TEST", 0, 22]]], ["For immunofluorescence, sections were incubated at 4\u00b0C with the primary rabbit anti-Ki-67 antibody followed by secondary FITClabelled goat-anti-rabbit (Abcam).", [["sections", "ANATOMY", 24, 32], ["rabbit", "ORGANISM", 72, 78], ["anti-Ki-67", "GENE_OR_GENE_PRODUCT", 79, 89], ["goat", "ORGANISM", 134, 138], ["Abcam", "GENE_OR_GENE_PRODUCT", 152, 157], ["primary rabbit anti-Ki-67 antibody", "PROTEIN", 64, 98], ["FITClabelled goat-anti-rabbit (Abcam)", "PROTEIN", 121, 158], ["rabbit", "SPECIES", 72, 78], ["goat", "SPECIES", 134, 138], ["anti-rabbit", "SPECIES", 139, 150], ["rabbit", "SPECIES", 72, 78], ["goat", "SPECIES", 134, 138], ["immunofluorescence", "TEST", 4, 22], ["the primary rabbit anti-Ki", "TEST", 60, 86]]], ["DAPI was used to detect nuclei.", [["nuclei", "ANATOMY", 24, 30], ["DAPI", "CHEMICAL", 0, 4], ["DAPI", "SIMPLE_CHEMICAL", 0, 4], ["nuclei", "CELLULAR_COMPONENT", 24, 30], ["DAPI", "TREATMENT", 0, 4]]], ["Photographs were taken using a high-resolution Olympus DP71 microscope.RNA extraction and quantitative RT-PCR (qRT-PCR)Total RNA was extracted from purified cells or different organs by the TRIzol method (Invitrogen, Milan, Italy) according to the manufacturer's protocol.", [["cells", "ANATOMY", 157, 162], ["organs", "ANATOMY", 176, 182], ["cells", "CELL", 157, 162], ["organs", "ORGAN", 176, 182], ["Olympus DP71 microscope", "DNA", 47, 70], ["purified cells", "CELL_TYPE", 148, 162], ["Photographs", "TEST", 0, 11], ["RNA extraction", "TEST", 71, 85], ["quantitative RT-PCR", "TEST", 90, 109], ["qRT", "TEST", 111, 114], ["PCR", "TEST", 115, 118], ["Total RNA", "PROBLEM", 119, 128], ["the TRIzol method", "TREATMENT", 186, 203], ["the manufacturer's protocol", "TREATMENT", 244, 271]]], ["The cDNA synthesis kit (BioRad, Milan, Italy) was used for reverse transcription according to the manufacturer's protocol.", [["The cDNA synthesis kit", "TEST", 0, 22], ["reverse transcription", "TREATMENT", 59, 80], ["the manufacturer's protocol", "TREATMENT", 94, 121]]], ["A real-time PCR amplification (PCR using CFX96 Touch\u2122 Real-Time PCR Detection System) was performed using SYBR Green QPCR master mix (Agilent Technologies, Milan, Italy) under the following conditions: 45 cycles of 95\u00b0C for 1 min, appropriate annealing temperature for 1 min, and 72\u00b0C for 30 sec.", [["A real-time PCR amplification", "TEST", 0, 29], ["PCR", "TEST", 31, 34], ["Touch", "TEST", 47, 52]]], ["All reactions were repeated at least three times independently to ensure the reproducibility of the results.ELISACytokine content was determined by enzyme-linked immunosorbent assays on tissue homogenates.", [["tissue homogenates", "ANATOMY", 186, 204], ["ELISACytokine", "SIMPLE_CHEMICAL", 108, 121], ["tissue homogenates", "ORGANISM_SUBSTANCE", 186, 204], ["ELISACytokine", "PROTEIN", 108, 121], ["ELISACytokine content", "TEST", 108, 129], ["enzyme", "TEST", 148, 154], ["immunosorbent assays", "TEST", 162, 182], ["tissue homogenates", "TEST", 186, 204]]], ["Briefly, ELISA plates were coated with 50 \u00b5l of anti-cytokine capture antibody at 4 \u00b0C overnight.", [["anti-cytokine capture antibody", "PROTEIN", 48, 78], ["ELISA plates", "TREATMENT", 9, 21], ["anti-cytokine capture antibody", "TREATMENT", 48, 78]]], ["Plates were then washed \u00d7 3 with 0.05% PBS-Tween (PBST) and coated for 1 h with the 150 \u00b5l 1% BSA/ PBS blocking buffer.", [["BSA", "CHEMICAL", 94, 97], ["Tween", "CHEMICAL", 43, 48], ["PBS-Tween", "SIMPLE_CHEMICAL", 39, 48], ["BSA", "SIMPLE_CHEMICAL", 94, 97], ["Plates", "TEST", 0, 6], ["PBS blocking buffer", "TREATMENT", 99, 118]]], ["Samples or standards were added in duplicates (50 \u00b5l per well) and incubated 2h at room temperature.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["Wells were washed \u00d7 3 with PBST and incubated with 50 \u00b5l of anti-cytokine detection antibody at 4 \u00b0C overnight.", [["anti-cytokine detection antibody", "PROTEIN", 60, 92], ["PBST", "TREATMENT", 27, 31], ["anti-cytokine detection antibody", "TREATMENT", 60, 92]]], ["Wells were then washed \u00d7 3 with PBST and incubated with 50 \u00b5l of avidin-HRP at room temperature for 30 min.", [["avidin-HRP", "SIMPLE_CHEMICAL", 65, 75], ["HRP", "PROTEIN", 72, 75], ["PBST", "TREATMENT", 32, 36], ["avidin", "TREATMENT", 65, 71]]], ["Thereafter, wells were washed \u00d7 5 with PBST and incubated with 50 \u00b5l per well of a substrate.", [["PBST", "TREATMENT", 39, 43], ["a substrate", "TREATMENT", 81, 92]]], ["The reaction was stopped after 15 min with 1 M H2SO4 and absorbance was measured using a TECAN microplate fluorescence reader (Infinite M200) at 405 nm and 570 nm.", [["H2SO4", "CHEMICAL", 47, 52], ["The reaction", "PROBLEM", 0, 12], ["a TECAN microplate fluorescence", "TREATMENT", 87, 118]]], ["The PCR primers sequences (5'-3') were as follows (Table S1 ).", [["PCR primers sequences", "DNA", 4, 25], ["The PCR primers sequences", "TEST", 0, 25]]], ["Table S1 .", [["S1", "ANATOMY", 6, 8]]], ["PCR primers sequences.In vitro 3-ICA antibacterial activityBacterial medium turbidity (McFarland standards, McF) was quantified through VITEK\u00ae 2 DensiCHEK TM Plus.", [["3-ICA", "CHEMICAL", 31, 36], ["3-ICA", "SIMPLE_CHEMICAL", 31, 36], ["PCR primers sequences", "DNA", 0, 21], ["PCR primers sequences", "TEST", 0, 21], ["vitro", "TEST", 25, 30], ["ICA antibacterial", "TREATMENT", 33, 50], ["Bacterial medium turbidity (McFarland standards", "TREATMENT", 59, 106], ["medium turbidity", "OBSERVATION", 69, 85]]], ["All bacterial strains (K. pneumoniae, KPC, P. aeruginosa, S. aureus) were inoculated in tryptic soy broth (TSB) medium (Sigma-Aldrich, Milan, Italy) and plated in untreated 96 well plate (flat bottom) to the final concentration of 0.25, 0.5 and 0.75 McF.", [["K. pneumoniae", "ORGANISM", 23, 36], ["KPC", "ORGANISM", 38, 41], ["P. aeruginosa", "ORGANISM", 43, 56], ["S. aureus", "ORGANISM", 58, 67], ["K. pneumoniae", "SPECIES", 23, 36], ["P. aeruginosa", "SPECIES", 43, 56], ["S. aureus", "SPECIES", 58, 67], ["K. pneumoniae", "SPECIES", 23, 36], ["P. aeruginosa", "SPECIES", 43, 56], ["S. aureus", "SPECIES", 58, 67], ["All bacterial strains", "PROBLEM", 0, 21], ["pneumoniae", "PROBLEM", 26, 36], ["KPC", "PROBLEM", 38, 41], ["P. aeruginosa", "PROBLEM", 43, 56], ["S. aureus", "PROBLEM", 58, 67], ["bacterial strains", "OBSERVATION", 4, 21], ["aureus", "OBSERVATION", 61, 67]]], ["1:2 ten scalar dilutions of 3-ICA and DMSO, as vehicle control, were made in TSB, before adding the bacteria.", [["3-ICA", "CHEMICAL", 28, 33], ["DMSO", "CHEMICAL", 38, 42], ["3-ICA", "CHEMICAL", 28, 33], ["DMSO", "CHEMICAL", 38, 42], ["3-ICA", "SIMPLE_CHEMICAL", 28, 33], ["DMSO", "SIMPLE_CHEMICAL", 38, 42], ["ten scalar dilutions", "TEST", 4, 24], ["DMSO", "TREATMENT", 38, 42], ["the bacteria", "PROBLEM", 96, 108]]], ["Bacterial growth has been monitored through ELISA microplate reader, measuring the OD 600 nm absorption at different time points (12h, 24h and 48h).Allergic Bronchopulmonary Aspergillosis (ABPA) and treatmentMice were anesthetized in a plastic cage by inhalation of 3% isoflurane (Forane Abbot) in oxygen before intranasal instillation.", [["Allergic Bronchopulmonary Aspergillosis", "DISEASE", 148, 187], ["ABPA", "DISEASE", 189, 193], ["isoflurane", "CHEMICAL", 269, 279], ["Forane", "CHEMICAL", 281, 287], ["oxygen", "CHEMICAL", 298, 304], ["isoflurane", "CHEMICAL", 269, 279], ["Forane", "CHEMICAL", 281, 287], ["oxygen", "CHEMICAL", 298, 304], ["Mice", "ORGANISM", 208, 212], ["isoflurane", "SIMPLE_CHEMICAL", 269, 279], ["Forane", "SIMPLE_CHEMICAL", 281, 287], ["oxygen", "SIMPLE_CHEMICAL", 298, 304], ["Mice", "SPECIES", 208, 212], ["Bacterial growth", "PROBLEM", 0, 16], ["Allergic Bronchopulmonary Aspergillosis", "PROBLEM", 148, 187], ["ABPA)", "TREATMENT", 189, 194], ["treatmentMice", "TREATMENT", 199, 212], ["a plastic cage", "TREATMENT", 234, 248], ["3% isoflurane (Forane Abbot)", "TREATMENT", 266, 294], ["oxygen", "TREATMENT", 298, 304], ["intranasal instillation", "TREATMENT", 312, 335], ["growth", "OBSERVATION_MODIFIER", 10, 16], ["Bronchopulmonary", "ANATOMY", 157, 173], ["Aspergillosis", "OBSERVATION", 174, 187]]], ["Mice received an i.p. and s.c. injection of 5 \u00b5g of cell culture filtrate Ags (CCFA) dissolved in incomplete freund's adjuvant (Sigma-Aldrich, Milan, Italy) followed by two consecutive intranasal injections, two and three weeks apart, of 20 \u00b5g CCFA.", [["cell", "ANATOMY", 52, 56], ["CCFA", "CHEMICAL", 244, 248], ["Mice", "ORGANISM", 0, 4], ["cell", "CELL", 52, 56], ["CCFA", "SIMPLE_CHEMICAL", 79, 83], ["Ags", "PROTEIN", 74, 77], ["Mice", "SPECIES", 0, 4], ["an i.p. and s.c. injection", "TREATMENT", 14, 40], ["cell culture filtrate Ags", "TREATMENT", 52, 77], ["incomplete freund's adjuvant", "TREATMENT", 98, 126], ["two consecutive intranasal injections", "TREATMENT", 169, 206]]], ["A week after the last intranasal challenge, mice received 10 7 A. fumigatus resting conidia.", [["conidia", "ANATOMY", 84, 91], ["mice", "ORGANISM", 44, 48], ["A. fumigatus", "ORGANISM", 63, 75], ["mice", "SPECIES", 44, 48], ["A. fumigatus", "SPECIES", 63, 75], ["mice", "SPECIES", 44, 48], ["A. fumigatus", "SPECIES", 63, 75], ["the last intranasal challenge", "TREATMENT", 13, 42]]], ["3-ICA aerosolized (166 \u00b5g/mL, 30 min daily) or PBS as a vehicle control were administered on day +27 and +28, between CCFA sensitization and A. fumigatus infection.", [["CCFA", "CHEMICAL", 118, 122], ["A. fumigatus infection", "DISEASE", 141, 163], ["3-ICA", "CHEMICAL", 0, 5], ["3-ICA", "SIMPLE_CHEMICAL", 0, 5], ["A. fumigatus", "ORGANISM", 141, 153], ["A. fumigatus", "SPECIES", 141, 153], ["A. fumigatus", "SPECIES", 141, 153], ["PBS", "TREATMENT", 47, 50], ["a vehicle control", "TREATMENT", 54, 71], ["CCFA sensitization", "PROBLEM", 118, 136], ["A. fumigatus infection", "PROBLEM", 141, 163], ["fumigatus infection", "OBSERVATION", 144, 163]]], ["Mice were sacrificed 6 days post infection.", [["infection", "DISEASE", 33, 42], ["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["Mice", "SPECIES", 0, 4], ["infection", "PROBLEM", 33, 42], ["infection", "OBSERVATION", 33, 42]]], ["Paraffin-", [["Paraffin", "TREATMENT", 0, 8]]]], "1cbd45be6a23bba602246faa1fa2b09970e2ebcc": [["ultimately reaching the brain.", [["brain", "ANATOMY", 24, 29], ["brain", "ORGAN", 24, 29], ["brain", "ANATOMY", 24, 29]]], ["SARS COV-2 spike glycoprotein consists of two subunits that are the S1 and S2.", [["COV-2", "GENE_OR_GENE_PRODUCT", 5, 10], ["S2", "GENE_OR_GENE_PRODUCT", 75, 77], ["SARS COV-2 spike glycoprotein", "PROTEIN", 0, 29], ["S1", "PROTEIN", 68, 70], ["S2", "PROTEIN", 75, 77], ["SARS COV", "TEST", 0, 8], ["2 spike glycoprotein", "TREATMENT", 9, 29], ["two subunits", "TREATMENT", 42, 54], ["S1", "ANATOMY_MODIFIER", 68, 70], ["S2", "ANATOMY", 75, 77]]], ["The S1 subunit consists of receptor binding domain (RBD) that binds with the host cell receptor to ACE-2.", [["cell", "ANATOMY", 82, 86], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 77, 95], ["ACE-2", "GENE_OR_GENE_PRODUCT", 99, 104], ["S1 subunit", "PROTEIN", 4, 14], ["receptor binding domain", "PROTEIN", 27, 50], ["RBD", "PROTEIN", 52, 55], ["host cell receptor", "PROTEIN", 77, 95], ["ACE", "PROTEIN", 99, 102], ["receptor binding domain (RBD)", "PROBLEM", 27, 56], ["ACE", "TEST", 99, 102], ["receptor binding", "OBSERVATION", 27, 43], ["host cell", "OBSERVATION", 77, 86]]], ["The second subunit is S2 which arbitrate fusion between viral and plasma membrane of host.", [["plasma membrane", "ANATOMY", 66, 81], ["S2", "GENE_OR_GENE_PRODUCT", 22, 24], ["plasma membrane", "CELLULAR_COMPONENT", 66, 81], ["S2", "PROTEIN", 22, 24], ["viral and plasma membrane of host", "TREATMENT", 56, 89], ["S2", "ANATOMY", 22, 24]]], ["It contains protrusions that allow the virus to bind a receptor on the host cell.", [["cell", "ANATOMY", 76, 80], ["host cell", "CELL", 71, 80], ["host cell", "CELL_TYPE", 71, 80], ["protrusions", "PROBLEM", 12, 23], ["the virus", "PROBLEM", 35, 44], ["protrusions", "OBSERVATION", 12, 23], ["host cell", "OBSERVATION", 71, 80]]]], "89763ca7bd242fac6c183c728bf57e4a6e75b2f5": [["Please cite this article as: Kar SK, Arafat SMY, Ransing R, Menon V, Padhy SK, Sharma P, Marthoenis M, Repeated celebrity suicide in India during COVID-19 crisis: An urgent call for attention, Asian Journal of Psychiatry (2020), doi: https://doi.org/10.", [["celebrity suicide", "DISEASE", 112, 129], ["SK", "ANATOMY", 75, 77]]], ["1016/j.ajp.2020.102382 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.", [["1016/j.ajp.2020.102382", "CHEMICAL", 0, 22]]], ["This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.", [["this version", "TREATMENT", 136, 148]]]], "PMC7499175": [["Accelerated pace of publications ::: IntroductionThe COVID-19 pandemic has resulted in a deluge of academic papers being published about the novel coronavirus in one of the greatest explosions of scientific literature ever observed.", [["coronavirus", "DISEASE", 147, 158], ["coronavirus", "ORGANISM", 147, 158], ["the novel coronavirus", "PROBLEM", 137, 158], ["coronavirus", "OBSERVATION", 147, 158], ["greatest", "OBSERVATION_MODIFIER", 173, 181], ["explosions", "OBSERVATION", 182, 192]]], ["This has led the preprint server \u201cbioRxiv\u201d to add a yellow banner warning on all new publications of coronavirus research saying: \u201cA reminder: these are preliminary reports that have not been peer-reviewed.", [["coronavirus", "DISEASE", 101, 112], ["coronavirus", "ORGANISM", 101, 112]]], ["Consequently, it is appropriate to ask why publish them?Accelerated pace of publications ::: IntroductionIn a technological era where a tweet or a Facebook feed may provoke more impact than a well-planned and diligently executed scientific project, we must rigorously question where the science stands currently, for the sake of transparency, rigour and public trust.", [["a Facebook feed", "TREATMENT", 145, 160]]], ["The quantity of manuscripts being published suggests that many of these may be observational or small trials with poor oversight, resulting in an inappropriately hasty publication.", [["an inappropriately hasty publication", "PROBLEM", 143, 179], ["quantity", "OBSERVATION_MODIFIER", 4, 12], ["manuscripts", "OBSERVATION", 16, 27], ["small", "OBSERVATION_MODIFIER", 96, 101], ["hasty publication", "OBSERVATION", 162, 179]]], ["But because good science requires discipline, caution, validation and replication, the current rapid pace of publications may be contributing to more confusion among the public and to an overall decline in scientific trust.7 The failure to conduct large-scale hypothesis-driven randomised controlled trials, in concert with haste for fast-track publications has added little to the treatment, and especially the prevention of the novel coronavirus.Failure of the clinical trial enterprise ::: IntroductionRandomised controlled trials (RCTs) are the gold standard test of whether or not a treatment is beneficial.8, 9, 10 The numerous biases and limitations of non-randomised, observational studies have been thoroughly documented and are detailed in the Table 1.", [["confusion", "DISEASE", 150, 159], ["coronavirus", "DISEASE", 436, 447], ["coronavirus", "ORGANISM", 436, 447], ["caution", "TREATMENT", 46, 53], ["validation", "TREATMENT", 55, 65], ["replication", "TREATMENT", 70, 81], ["more confusion", "PROBLEM", 145, 159], ["The failure", "PROBLEM", 225, 236], ["large-scale hypothesis", "PROBLEM", 248, 270], ["the treatment", "TREATMENT", 378, 391], ["the novel coronavirus", "PROBLEM", 426, 447], ["IntroductionRandomised controlled trials (RCTs", "TREATMENT", 493, 539], ["a treatment", "TREATMENT", 586, 597], ["observational studies", "TEST", 676, 697], ["failure", "OBSERVATION", 229, 236], ["large", "OBSERVATION_MODIFIER", 248, 253], ["numerous", "OBSERVATION_MODIFIER", 625, 633], ["biases", "OBSERVATION", 634, 640]]], ["It must be emphasized, however, that underpowered and poorly conducted RCTs are equally prone to bias and spurious findings.11 Regretfully, observational, poor-quality randomised and good-quality randomised studies are allocated similar press coverage and dissemination.12 The growing access to large sets of data from thousands of patients and multiple data sources (i.e., \u201cbig data\u201d) has prompted many researchers to erroneously claim an accurate determination of treatment effects from non-randomized studies.13,14 Although, this approach may be used in unique settings wherein it is not feasible to perform a RCT, it should not be used to replace RCTs in settings where RCTs can (and should) be performed - as in the current coronavirus crisis.10,15, 16, 17, 18 Additionally, using \u201cbig data\u201d in the absence of a prespecified power calculation, expected event rates, treatment effects, and follow-up time (i.e., all prespecified parameters of RCTs) is fraught with errors.19, 20, 21Table 1.Failure of the clinical trial enterprise ::: IntroductionDuring the COVID-19 outbreak many observational studies claiming treatment effects have been reported in top tier medical journals with the inherent limitations above (and in Table 1) described22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35; together with a few, small-scale, and/or open-label RCTs,36, 37, 38, 39, 40, 41, 42, 43 and no large-scale, international, well-powered, double-blinded RCT.Failure of the clinical trial enterprise ::: IntroductionObservational studies can also jeopardize ongoing RCTs.", [["coronavirus", "DISEASE", 729, 740], ["patients", "ORGANISM", 332, 340], ["coronavirus", "ORGANISM", 729, 740], ["patients", "SPECIES", 332, 340], ["spurious findings", "PROBLEM", 106, 123], ["similar press coverage", "TREATMENT", 229, 251], ["dissemination", "PROBLEM", 256, 269], ["treatment effects", "TREATMENT", 466, 483], ["non-randomized studies", "TEST", 489, 511], ["a RCT", "TREATMENT", 611, 616], ["RCTs", "TREATMENT", 651, 655], ["RCTs", "TEST", 674, 678], ["the current coronavirus crisis", "PROBLEM", 717, 747], ["the COVID", "TREATMENT", 1058, 1067], ["observational studies", "TEST", 1085, 1106], ["treatment effects", "TREATMENT", 1116, 1133], ["IntroductionObservational studies", "TEST", 1501, 1534], ["spurious", "OBSERVATION", 106, 114], ["large", "OBSERVATION_MODIFIER", 295, 300], ["coronavirus crisis", "OBSERVATION", 729, 747], ["small", "OBSERVATION_MODIFIER", 1321, 1326]]], ["For example, the recent publication (and subsequent retraction) of an observational study showing a possible deleterious effect of hydroxychloroquine and chloroquine for the treatment of COVID-1932 has prompted many ongoing trials to withhold the hydroxychloroquine arm.", [["hydroxychloroquine", "CHEMICAL", 131, 149], ["chloroquine", "CHEMICAL", 154, 165], ["COVID-1932", "CHEMICAL", 187, 197], ["hydroxychloroquine", "CHEMICAL", 247, 265], ["hydroxychloroquine", "CHEMICAL", 131, 149], ["chloroquine", "CHEMICAL", 154, 165], ["COVID-1932", "CHEMICAL", 187, 197], ["hydroxychloroquine", "CHEMICAL", 247, 265], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 131, 149], ["chloroquine", "SIMPLE_CHEMICAL", 154, 165], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 247, 265], ["subsequent retraction", "TREATMENT", 41, 62], ["an observational study", "TEST", 67, 89], ["hydroxychloroquine", "TREATMENT", 131, 149], ["chloroquine", "TREATMENT", 154, 165], ["the hydroxychloroquine arm", "TREATMENT", 243, 269], ["publication", "OBSERVATION", 24, 35]]], ["Because of the context, the decision of pausing the randomisation to hydroxychloroquine might have been inevitable, simply because the patients started to express concern about participating in the trials.44 While intermediate analysis could be informative, much more informative is to complete the trials as planned.45 The recent retraction of manuscripts with data emanating from Surgisphere,23,32 highlights the failure of adherence to good science practices (access to the original data source denied by Surgisphere) and of peer-reviewing and editorial oversight (not having vetted quality control of the database before their publication).", [["hydroxychloroquine", "CHEMICAL", 69, 87], ["hydroxychloroquine", "CHEMICAL", 69, 87], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 69, 87], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["hydroxychloroquine", "TREATMENT", 69, 87], ["retraction", "OBSERVATION_MODIFIER", 331, 341]]], ["The confusion caused by these episodes expose to the \u201cdouble whammy\u201d of a) further disruption of RCT timely evidence generation and b) of loss of confidence of the patients eligible for inclusion in the ongoing clinical trials.", [["confusion", "DISEASE", 4, 13], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["The confusion", "PROBLEM", 0, 13]]], ["In a constructive vein we have provided a framework to support and enhance the efforts of editors and reviewers in the handling of observational analyses is provided in the Table 2.Failure of the clinical trial enterprise ::: IntroductionAlong with the multiple observational studies, some RCTs have also been published.", [["vein", "ANATOMY", 18, 22], ["vein", "MULTI-TISSUE_STRUCTURE", 18, 22], ["observational analyses", "TEST", 131, 153], ["the multiple observational studies", "TEST", 249, 283], ["some RCTs", "TREATMENT", 285, 294], ["vein", "ANATOMY", 18, 22]]], ["A critical interpretation of these RCTs is presented in the Table 3.", [["these RCTs", "TEST", 29, 39]]], ["Overall our critique demonstrates a clear failure of the clinical trial enterprise, revealing a lack of coordination and international cooperation required to facilitate large, high quality RCTs that could potentially respond to the patients` needs in a scientifically valid and timely manner.46", [["patients", "ORGANISM", 233, 241], ["patients", "SPECIES", 233, 241], ["large, high quality RCTs", "PROBLEM", 170, 194], ["clear", "OBSERVATION_MODIFIER", 36, 41], ["failure", "OBSERVATION", 42, 49], ["large", "OBSERVATION_MODIFIER", 170, 175]]]], "b3889634cbf4863aaf031d1deaa355c9a0901dc9": [["INTRODUCTIONCOVID19, caused by the novel coronavirus SARS-CoV-2 (CoV-2) (Zhou et al., 2020) , was declared a global pandemic by the World Health Organization on March 11 th 2020.", [["coronavirus SARS-CoV-2", "ORGANISM", 41, 63], ["CoV-2", "ORGANISM", 65, 70], ["coronavirus SARS-CoV", "SPECIES", 41, 61], ["the novel coronavirus SARS", "PROBLEM", 31, 57], ["CoV", "TEST", 58, 61]]], ["As of April 21 st 2020, the disease had spread to over 2.5 million cases worldwide, straining the global healthcare infrastructure, and is rapidly becoming a leading cause of death (Keating and Esteban, 2020) .INTRODUCTIONMedical interventions to address COVID19 are lacking both in the context of prophylactic vaccination approaches, as well as pharmaceutical interventions to treat infected patients.", [["death", "DISEASE", 175, 180], ["COVID19", "GENE_OR_GENE_PRODUCT", 255, 262], ["patients", "ORGANISM", 393, 401], ["patients", "SPECIES", 393, 401], ["the disease", "PROBLEM", 24, 35], ["death", "PROBLEM", 175, 180], ["COVID19", "TREATMENT", 255, 262], ["prophylactic vaccination approaches", "TREATMENT", 298, 333], ["pharmaceutical interventions", "TREATMENT", 346, 374], ["disease", "OBSERVATION", 28, 35]]], ["Some countries such as Singapore have demonstrated the feasibility of contact tracing when sufficient testing capacities are available to quarantine exposed individuals and contain disease spread (Anderson et al., 2020) .", [["contact tracing", "TEST", 70, 85], ["sufficient testing capacities", "PROBLEM", 91, 120]]], ["These policies include closure of nonessential workplaces and schools, as well as policies on physical spacing when in public aimed at preventing viral transmission to reduce the number of new COVID19 cases.INTRODUCTIONMathematical models of COVID19 spread have indicated that social distancing policy will likely reduce the spread of CoV-2 (Kissler et al., 2020) .", [["COVID19", "GENE_OR_GENE_PRODUCT", 242, 249], ["CoV-2", "ORGANISM", 335, 340], ["closure of nonessential workplaces", "TREATMENT", 23, 57], ["COVID19 spread", "PROBLEM", 242, 256], ["closure", "OBSERVATION", 23, 30]]], ["Case reports from regions nearby Hubei province where the virus originated have demonstrated social distancing policies will reduce viral transmission (Leung et al., 2020) , however the efficacy of the approach has yet to be evaluated on a global scale.", [["the virus", "PROBLEM", 54, 63], ["a global scale", "TEST", 238, 252]]], ["Here, using data from 53 nations we assess the efficacy of social distancing approaches and find that social distancing significantly prevents spread of COVID19, resulting in an estimated 66% reduction in new COVID19 cases.Data Sources.All data were acquired on April 21 st 2020.", [["All data", "TEST", 236, 244]]], ["Daily case numbers for COVID19 and population numbers were acquired from https://www.worldometers.info/coronavirus/.", [["COVID19", "TEST", 23, 30], ["population numbers", "TEST", 35, 53]]], ["Countries were considered for inclusion if they had over 500 cases of COVID19, and at least 10 days of data prior to and following implementation of social distancing policy (or equivalent time period in countries without a social distancing policy).", [["COVID19", "TREATMENT", 70, 77]]], ["Countries with regional social distancing policies were excluded from analysis.Data Sources.Data Analysis.", [["Data Analysis", "TEST", 92, 105]]], ["All data analysis was performed in MATLAB R2019a.", [["All data analysis", "TEST", 0, 17]]], ["No reuse allowed without permission.Data Sources.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Data Sources.The copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.", [["The copyright holder", "TREATMENT", 197, 217], ["med", "ANATOMY", 128, 131]]], ["1101 Cases0\u00b7exp(k spread \u00b7t), where Cases is cases per million inhabitants, Cases0 is the number of cases per million inhabitants at the initial time point, k spread is the COVID19 spread rate, and t is the time point in days.", [["Cases0\u00b7exp", "TEST", 5, 15]]], ["For global modeling of COVID19 spread, the above equation was utilized is a generalized linear mixed-effects model taking each country as a random effect.", [["COVID19", "GENE_OR_GENE_PRODUCT", 23, 30], ["COVID19", "DNA", 23, 30], ["COVID19 spread", "PROBLEM", 23, 37], ["a generalized linear mixed-effects", "PROBLEM", 74, 108], ["generalized", "OBSERVATION_MODIFIER", 76, 87], ["linear", "OBSERVATION_MODIFIER", 88, 94], ["mixed", "OBSERVATION_MODIFIER", 95, 100]]], ["To estimate prevented number of cases, the change in COVID19 spread rate in countries with social distancing policies was equated to that of those without social distancing.", [["COVID19", "PROTEIN", 53, 60], ["the change", "PROBLEM", 39, 49], ["COVID19 spread rate", "TREATMENT", 53, 72]]], ["Final total number cases was determined after 14 days of spread.RESULTSIn order to assess the efficacy of social distancing policies, we began by quantifying the COVID19 spread rate as defined by an exponential growth function both before and after social distancing policies were enacted.", [["social distancing policies", "TREATMENT", 249, 275]]], ["As the rate of disease spreading may be influenced by other temporal features such as weather patterns or disproportional infection of immunocompromised individuals at early stages, we further quantified COVID19 spread rates over time-matched intervals for nations without social distancing policies.", [["infection", "DISEASE", 122, 131], ["COVID19", "PROTEIN", 204, 211], ["disease spreading", "PROBLEM", 15, 32], ["disproportional infection", "PROBLEM", 106, 131], ["immunocompromised individuals", "PROBLEM", 135, 164], ["disease", "OBSERVATION", 15, 22], ["disproportional", "OBSERVATION_MODIFIER", 106, 121], ["infection", "OBSERVATION", 122, 131]]], ["In Norway, pre-social distancing COVID19 spread rate was 0.28 ( Figure 1A) , dropping to 0.07 following social distancing ( Figure 1B) for a net change of -0.21.", [["spread rate", "TEST", 41, 52], ["a net change", "TEST", 139, 151]]], ["When analyzing spread rate in Sweden over equivalent time periods we found that Sweden only dropped from 0.13 (Figure 1C) , to 0.10 ( Figure 1D ) for a net change of -0.03, 7-fold lower than observed in Norway.", [["a net change", "TEST", 150, 162]]], ["Normalization of spreading rates on a per country basis helps to mitigate variances based on population demographics, climate, healthcare infrastructure, and other factors that vary across nations.", [["spreading rates", "PROBLEM", 17, 32], ["spreading", "OBSERVATION_MODIFIER", 17, 26]]], ["We applied this approach to 53 countries total for which sufficient data was available ( Figure 1E ).", [["this approach", "TREATMENT", 11, 24]]], ["Comparing the resulting changes in COVID19 spread rate we found that countries which enacted social distancing policies demonstrated a significantly larger reduction in COVID19 spread rates (p = 5.3x10 -4 , Figure 1F ).RESULTSIn order to assess the benefit of this reduction in COVID19 spread rates, we refined our calculations using generalized linear mixed effect models taking each country as a random effect.RESULTSThis approach again recapitulated the larger drop in COVID19 spread rates observed in countries All rights reserved.", [["COVID19", "PROTEIN", 35, 42], ["COVID19 spread rate", "TEST", 35, 54], ["a significantly larger reduction", "PROBLEM", 133, 165], ["this reduction", "TREATMENT", 260, 274], ["our calculations", "TEST", 311, 327], ["generalized linear mixed effect models", "TREATMENT", 334, 372], ["the larger drop", "PROBLEM", 453, 468], ["COVID19 spread rates", "TREATMENT", 472, 492], ["larger", "OBSERVATION_MODIFIER", 149, 155], ["reduction", "OBSERVATION_MODIFIER", 156, 165], ["larger", "OBSERVATION_MODIFIER", 457, 463], ["drop", "OBSERVATION_MODIFIER", 464, 468]]], ["No reuse allowed without permission.RESULTS(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.RESULTSThe copyright holder for this preprint this version posted April 29, 2020. . https://doi.org/10.1101/2020.04.23.20077271 doi: medRxiv preprint with social distancing policies (Figure 2A) .", [["med", "ANATOMY", 122, 125]]], ["To quantify the healthcare benefits resulting from this reduction in spread rate, we calculated COVID19 spread rates in countries with social distancing policies both using the model directly fit to the data, as well as correcting for the reduction in COVID19 spread rate observed following implementation of social distancing policies ( Figure 2B ).", [["this reduction in spread rate", "PROBLEM", 51, 80], ["social distancing policies", "TREATMENT", 135, 161], ["the reduction in COVID19 spread rate", "TREATMENT", 235, 271]]], ["After accounting for number of inhabitants, this approach indicates that over a two week period social distancing prevented over half a million cases of COVID19 in the 26 nations with social distancing policies, representing a 66% reduction in new COVID19 cases (Figure 2C ).DISCUSSIONOur analysis of COVID19 spread rates in 53 countries quantifies the effects of social distancing at preventing CoV-2 transmission.", [["CoV-2", "GENE_OR_GENE_PRODUCT", 396, 401], ["COVID19", "DNA", 301, 308], ["CoV-2", "SPECIES", 396, 401], ["COVID19", "TREATMENT", 153, 160], ["a 66% reduction", "TREATMENT", 225, 240], ["COVID19 spread rates", "TREATMENT", 301, 321]]], ["While numerous factors such as population density, healthcare infrastructure, testing rates, climate, population characteristics, and more, likely contribute to rate of COVID19 spread, this study focused on the change in COVID19 spread rate following implementation of social distancing policies as an internal control for these variables.", [["COVID19", "GENE_OR_GENE_PRODUCT", 169, 176], ["population density", "PROBLEM", 31, 49], ["testing rates", "TEST", 78, 91], ["COVID19 spread", "PROBLEM", 169, 183], ["this study", "TEST", 185, 195], ["social distancing policies", "TREATMENT", 269, 295], ["an internal control", "TREATMENT", 299, 318], ["population", "OBSERVATION_MODIFIER", 31, 41], ["density", "OBSERVATION", 42, 49]]], ["This analysis found that social distancing policies significantly reduced spreading rates compared to time-matched intervals in nations that did not implement social distancing policies.", [["This analysis", "TEST", 0, 13]]], ["While social distancing policies may have negative economic impacts (Eichenbaum et al., 2020) , this analysis suggests that this containment approach has yielded significant positive health outcomes.DISCUSSIONAs testing capacities increase, contact tracing may provide an alternative to minimize economic impacts by only quarantining those who are exposed to infected individuals.", [["this analysis", "TEST", 96, 109], ["significant positive health outcomes", "PROBLEM", 162, 198], ["contact tracing", "TEST", 241, 256], ["significant", "OBSERVATION_MODIFIER", 162, 173], ["positive", "OBSERVATION_MODIFIER", 174, 182], ["health outcomes", "OBSERVATION", 183, 198]]], ["This approach has already demonstrated high efficacy in the context of nations with high testing capacity (Anderson et al., 2020) .", [["high", "OBSERVATION_MODIFIER", 39, 43], ["efficacy", "OBSERVATION_MODIFIER", 44, 52]]], ["Technological advancements, such as potential phone-based contact tracing Apps, may further enhance the benefit achieved by contact tracing approaches (Ferretti et al., 2020) .DISCUSSIONThe emergence of further refined data will allow for more precise quantification of various approaches to mitigate the spread of COVID19.", [["COVID19", "CHEMICAL", 315, 322], ["COVID19", "GENE_OR_GENE_PRODUCT", 315, 322], ["COVID19", "PROTEIN", 315, 322], ["COVID19", "TREATMENT", 315, 322]]], ["This analysis based on 53 countries indicates that social distancing can serve as a critical preventative measure until prophylactic measures and larger population immunity are generated.DISCUSSIONAll rights reserved.", [["This analysis", "TEST", 0, 13], ["a critical preventative measure", "TREATMENT", 82, 113], ["prophylactic measures", "TREATMENT", 120, 141], ["larger population immunity", "TREATMENT", 146, 172]]], ["No reuse allowed without permission.DISCUSSION(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DISCUSSIONThe copyright holder for this preprint this version posted April 29, 2020. .", [["med", "ANATOMY", 125, 128]]], ["Reduction in COVID19 spread rates in countries with social distancing.", [["COVID19", "GENE_OR_GENE_PRODUCT", 13, 20], ["COVID19", "PROTEIN", 13, 20], ["Reduction", "TREATMENT", 0, 9], ["spread", "OBSERVATION_MODIFIER", 21, 27], ["rates", "OBSERVATION_MODIFIER", 28, 33]]], ["No reuse allowed without permission.FIGURES(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.FIGURESThe copyright holder for this preprint this version posted April 29, 2020. .(A-D)Fitting of COVID19 spread rates in Norway (A-B) prior to social distancing policy implementation (A) and after social distancing policy implementation (B) as well as Sweden (C-D) in a time period equated to pre-social distancing in Norway (C) and post-social distancing in Norway (D).(A-D)(E) Change in COVID19 spread before and after social distancing in countries with social distancing policies (blue), or time equated periods in countries with no social distancing policies (red).(A-D)(F) Dot plot of values shown in (E) showing reduction in COVID19 spread following implementation of social distancing policies.", [["Change in COVID19 spread", "PROBLEM", 559, 583], ["Dot plot of values", "TEST", 759, 777], ["reduction in COVID19 spread", "PROBLEM", 799, 826], ["med", "ANATOMY", 122, 125], ["reduction", "OBSERVATION_MODIFIER", 799, 808]]], ["Rank-sum test.Figure 2.", [["Rank-sum test", "TEST", 0, 13]]], ["Prevention of new COVID19 cases by social distancing policies.(A) Change in COVID19 spread rates following implementation of social distancing policies (blue), or time-equated periods in countries with no social distancing policies (red).", [["Change in COVID19 spread rates", "TREATMENT", 66, 96], ["new", "OBSERVATION_MODIFIER", 14, 17]]], ["Data were fit using a generalized linear mixed-effects model taking each country as a random effect.", [["a generalized linear mixed-effects", "PROBLEM", 20, 54]]], ["Bars represent change in regression coefficient \u00b1 standard error.Figure 2.", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["change", "OBSERVATION_MODIFIER", 15, 21]]], ["Prevention of new COVID19 cases by social distancing policies.(B) Modeling of new COVID19 cases per million inhabitants in countries with social distancing policies using either model fit directly to data following implementation of social distancing policies (blue), or after correcting for the observed reduction in COVID19 spread rates associated with social distancing policies (red).", [["the observed reduction", "PROBLEM", 292, 314], ["COVID19 spread rates", "TREATMENT", 318, 338], ["new", "OBSERVATION_MODIFIER", 14, 17], ["new", "OBSERVATION_MODIFIER", 78, 81]]], ["Prevention of new COVID19 cases by social distancing policies.(C) Estimation of total new cases over a two-week period if countries had not implemented social distancing policies (red), with implementation of social distancing policies (light blue), and actual new cases (dark blue).", [["new", "OBSERVATION_MODIFIER", 14, 17]]], ["Bars represent number of COVID19 cases in the countries with social distancing policies \u00b1 standard error.", [["Bars", "GENE_OR_GENE_PRODUCT", 0, 4]]]], "PMC7185824": [["BackgroundInfluenza results in significant morbidity and mortality in the U.S and worldwide [1], and this is exacerbated by bacterial co-infections during both seasonal and pandemic influenza years [2], [3], [4].", [["Influenza", "DISEASE", 10, 19], ["influenza", "DISEASE", 182, 191], ["BackgroundInfluenza", "PROBLEM", 0, 19], ["significant morbidity", "PROBLEM", 31, 52], ["bacterial co-infections", "PROBLEM", 124, 147], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["morbidity", "OBSERVATION", 43, 52], ["bacterial co-infections", "OBSERVATION", 124, 147]]], ["During the most severe influenza pandemic recorded, in 1918\u20131919, when an estimated 675,000 people died in the United States [5], [6], epidemiologic, clinical and pathologic data indicate that the majority of influenza patients died from bacterial pneumonia rather than from the influenza virus itself.", [["influenza pandemic", "DISEASE", 23, 41], ["influenza", "DISEASE", 209, 218], ["pneumonia", "DISEASE", 248, 257], ["influenza", "DISEASE", 279, 288], ["people", "ORGANISM", 92, 98], ["influenza", "ORGANISM", 209, 218], ["patients", "ORGANISM", 219, 227], ["influenza virus", "ORGANISM", 279, 294], ["people", "SPECIES", 92, 98], ["patients", "SPECIES", 219, 227], ["the most severe influenza pandemic", "PROBLEM", 7, 41], ["pathologic data", "TEST", 163, 178], ["influenza", "PROBLEM", 209, 218], ["bacterial pneumonia", "PROBLEM", 238, 257], ["the influenza virus itself", "PROBLEM", 275, 301], ["bacterial", "OBSERVATION_MODIFIER", 238, 247], ["pneumonia", "OBSERVATION", 248, 257], ["influenza virus", "OBSERVATION", 279, 294]]], ["Bacterial co-infections should thus be studied in order to devise effective preventative and therapeutic strategies [2], [3], [7].BackgroundInfluenza virus has been shown to have complex effects on the human lung, priming the respiratory tract for synergistic pathogenesis with a bacterial co-infection [8].", [["lung", "ANATOMY", 208, 212], ["respiratory tract", "ANATOMY", 226, 243], ["bacterial co-infection", "DISEASE", 280, 302], ["[3]", "SIMPLE_CHEMICAL", 121, 124], ["[7]", "SIMPLE_CHEMICAL", 126, 129], ["Influenza virus", "ORGANISM", 140, 155], ["human", "ORGANISM", 202, 207], ["lung", "ORGAN", 208, 212], ["respiratory tract", "ORGANISM_SUBDIVISION", 226, 243], ["Influenza virus", "SPECIES", 140, 155], ["human", "SPECIES", 202, 207], ["Influenza virus", "SPECIES", 140, 155], ["human", "SPECIES", 202, 207], ["Bacterial co-infections", "PROBLEM", 0, 23], ["BackgroundInfluenza virus", "PROBLEM", 130, 155], ["complex effects on the human lung", "PROBLEM", 179, 212], ["synergistic pathogenesis", "PROBLEM", 248, 272], ["a bacterial co-infection", "PROBLEM", 278, 302], ["co-infections", "OBSERVATION", 10, 23], ["Influenza virus", "OBSERVATION", 140, 155], ["lung", "ANATOMY", 208, 212], ["respiratory tract", "ANATOMY", 226, 243], ["bacterial", "OBSERVATION_MODIFIER", 280, 289], ["co-infection", "OBSERVATION", 290, 302]]], ["Morbidity and mortality are increased when bacterial pneumonia complicates influenza infection as compared with bacterial pneumonia in the absence of influenza infection [9], [10].BackgroundDuring the 1918 and 1968\u20131969 pandemics, Streptococcus pneumoniae was likely the most common co-pathogen [3], [11].", [["pneumonia", "DISEASE", 53, 62], ["influenza infection", "DISEASE", 75, 94], ["pneumonia", "DISEASE", 122, 131], ["influenza infection", "DISEASE", 150, 169], ["Streptococcus pneumoniae", "DISEASE", 231, 255], ["Streptococcus pneumoniae", "ORGANISM", 231, 255], ["Streptococcus pneumoniae", "SPECIES", 231, 255], ["Streptococcus pneumoniae", "SPECIES", 231, 255], ["Morbidity", "PROBLEM", 0, 9], ["mortality", "PROBLEM", 14, 23], ["bacterial pneumonia", "PROBLEM", 43, 62], ["influenza infection", "PROBLEM", 75, 94], ["bacterial pneumonia", "PROBLEM", 112, 131], ["influenza infection", "PROBLEM", 150, 169], ["Streptococcus pneumoniae", "PROBLEM", 231, 255], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["bacterial", "OBSERVATION_MODIFIER", 43, 52], ["pneumonia", "OBSERVATION", 53, 62], ["bacterial", "OBSERVATION_MODIFIER", 112, 121], ["pneumonia", "OBSERVATION", 122, 131], ["influenza", "OBSERVATION", 150, 159], ["Streptococcus pneumoniae", "OBSERVATION", 231, 255]]], ["In the 1957\u20131958 pandemic, many reports identified Staphylococcus aureus as the most frequently cultured co-pathogen [3], [12], [13].", [["Staphylococcus aureus", "DISEASE", 51, 72], ["Staphylococcus aureus", "ORGANISM", 51, 72], ["[12]", "SIMPLE_CHEMICAL", 122, 126], ["Staphylococcus aureus", "SPECIES", 51, 72], ["Staphylococcus aureus", "SPECIES", 51, 72], ["Staphylococcus aureus", "PROBLEM", 51, 72], ["Staphylococcus aureus", "OBSERVATION", 51, 72]]], ["More recently S. aureus has been increasingly found in cases of fulminant pneumonia complicating influenza infection [14], [15].", [["pneumonia", "DISEASE", 74, 83], ["influenza infection", "DISEASE", 97, 116], ["S. aureus", "ORGANISM", 14, 23], ["S. aureus", "SPECIES", 14, 23], ["S. aureus", "SPECIES", 14, 23], ["S. aureus", "PROBLEM", 14, 23], ["fulminant pneumonia", "PROBLEM", 64, 83], ["influenza infection", "PROBLEM", 97, 116], ["aureus", "OBSERVATION", 17, 23], ["fulminant", "OBSERVATION_MODIFIER", 64, 73], ["pneumonia", "OBSERVATION", 74, 83]]], ["Haemophilus influenzae, with the introduction of the H. influenzae type B conjugate vaccine in 1985 [16], and Streptococcus pyogenes have decreased in prevalence over time [17].", [["Haemophilus influenzae", "DISEASE", 0, 22], ["Streptococcus pyogenes", "DISEASE", 110, 132], ["Haemophilus influenzae", "ORGANISM", 0, 22], ["H. influenzae type B conjugate vaccine", "ORGANISM", 53, 91], ["Streptococcus pyogenes", "ORGANISM", 110, 132], ["Haemophilus influenzae", "SPECIES", 0, 22], ["H. influenzae", "SPECIES", 53, 66], ["Streptococcus pyogenes", "SPECIES", 110, 132], ["Haemophilus influenzae", "SPECIES", 0, 22], ["H. influenzae type B", "SPECIES", 53, 73], ["Streptococcus pyogenes", "SPECIES", 110, 132], ["Haemophilus influenzae", "PROBLEM", 0, 22], ["the H. influenzae type B conjugate vaccine", "TREATMENT", 49, 91], ["Streptococcus pyogenes", "PROBLEM", 110, 132], ["influenzae", "OBSERVATION", 12, 22]]], ["Vaccination, novel antibiotics, and probably more importantly, viral or bacterial strain-related differences account for shifts in etiology of the most common bacterial co-infections [8].BackgroundA novel pandemic influenza A strain, influenza A (H1N1) pdm09, emerged in 2009.", [["bacterial co-infections", "DISEASE", 159, 182], ["influenza A", "DISEASE", 214, 225], ["influenza A (H1N1) pdm09", "DISEASE", 234, 258], ["pandemic influenza A strain", "ORGANISM", 205, 232], ["influenza A (H1N1) pdm09", "ORGANISM", 234, 258], ["pandemic influenza A", "SPECIES", 205, 225], ["influenza A (H1N1", "SPECIES", 234, 251], ["influenza A (H1N1) pdm09", "SPECIES", 234, 258], ["Vaccination", "TREATMENT", 0, 11], ["novel antibiotics", "TREATMENT", 13, 30], ["bacterial strain", "PROBLEM", 72, 88], ["the most common bacterial co-infections", "PROBLEM", 143, 182], ["BackgroundA novel pandemic influenza A strain", "PROBLEM", 187, 232], ["influenza", "PROBLEM", 234, 243], ["pdm09", "PROBLEM", 253, 258], ["bacterial strain", "OBSERVATION", 72, 88], ["pandemic", "OBSERVATION_MODIFIER", 205, 213], ["influenza", "OBSERVATION", 214, 223]]], ["Reported rates of bacterial co-infection among severely ill patients varied between 17.5% and 25% for community-acquired influenza patients in the 2009\u20132010 season [18], [19] and 33% in a study of combined community-acquired and hospital-acquired influenza patients [20].", [["bacterial co-infection", "DISEASE", 18, 40], ["severely ill", "DISEASE", 47, 59], ["influenza", "DISEASE", 121, 130], ["influenza", "DISEASE", 247, 256], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 257, 265], ["bacterial co-infection", "PROBLEM", 18, 40], ["a study", "TEST", 186, 193], ["bacterial", "OBSERVATION_MODIFIER", 18, 27], ["co-infection", "OBSERVATION", 28, 40]]], ["In these and other studies the most common community-acquired pathogens included S. pneumoniae and then S. aureus[10].", [["S. pneumoniae", "DISEASE", 81, 94], ["S. pneumoniae", "ORGANISM", 81, 94], ["S. aureus", "ORGANISM", 104, 113], ["S. pneumoniae", "SPECIES", 81, 94], ["S. aureus", "SPECIES", 104, 113], ["S. pneumoniae", "SPECIES", 81, 94], ["S. aureus", "SPECIES", 104, 113], ["other studies", "TEST", 13, 26], ["acquired pathogens", "PROBLEM", 53, 71], ["S. pneumoniae", "PROBLEM", 81, 94], ["S. aureus", "PROBLEM", 104, 113], ["pneumoniae", "OBSERVATION", 84, 94], ["aureus", "OBSERVATION", 107, 113]]], ["The risk of co-infection and spectrum of bacterial species has not been studied during the 2013\u20132014 season, the first postpandemic year in which influenza A (H1N1) pdm was the predominant circulating influenza strain.ObjectivesWe recently completed a retrospective study of 507 patients with severe influenza treated in intensive care units (ICUs) of 33 U.S. hospitals during the 2013\u20132014 influenza season [21].", [["co-infection", "DISEASE", 12, 24], ["influenza", "DISEASE", 146, 155], ["influenza", "DISEASE", 300, 309], ["influenza", "DISEASE", 391, 400], ["influenza A (H1N1) pdm", "ORGANISM", 146, 168], ["patients", "ORGANISM", 279, 287], ["patients", "SPECIES", 279, 287], ["co-infection", "PROBLEM", 12, 24], ["bacterial species", "PROBLEM", 41, 58], ["influenza A (H1N1) pdm", "PROBLEM", 146, 168], ["the predominant circulating influenza strain", "PROBLEM", 173, 217], ["a retrospective study", "TEST", 250, 271], ["severe influenza", "PROBLEM", 293, 309], ["co-infection", "OBSERVATION", 12, 24], ["bacterial species", "OBSERVATION", 41, 58], ["predominant", "OBSERVATION_MODIFIER", 177, 188], ["circulating influenza strain", "OBSERVATION", 189, 217], ["severe", "OBSERVATION_MODIFIER", 293, 299], ["influenza", "OBSERVATION", 300, 309]]], ["The objectives of the present study were to evaluate bacterial and viral co-infection in this cohort, to describe the spectrum of co-infections and to determine their clinical impact.Data collected ::: Study designData for this study were abstracted by a physician from each center\u2019s electronic health record (EHR) and entered into a REDCap database [22].", [["bacterial and viral co-infection", "DISEASE", 53, 85], ["co-infections", "DISEASE", 130, 143], ["the present study", "TEST", 18, 35], ["bacterial and viral co-infection", "PROBLEM", 53, 85], ["co-infections", "PROBLEM", 130, 143], ["Study designData", "TEST", 202, 218], ["this study", "TEST", 223, 233], ["viral", "OBSERVATION_MODIFIER", 67, 72], ["co-infection", "OBSERVATION", 73, 85], ["co-infections", "OBSERVATION", 130, 143]]], ["Data abstracted and study site information were previously described [21].Data collected ::: Study designBacterial co-infection was defined in patients having one or more isolates obtained from a blood culture and/or a pleural fluid, sputum, tracheal or bronchoscopic sample if the isolate was a pathogen thought to be causing a true infection in the opinion of the treating physician and if the isolate was collected within 30 days of ICU admission or present on arrival to the ICU.", [["blood", "ANATOMY", 196, 201], ["pleural fluid", "ANATOMY", 219, 232], ["sputum", "ANATOMY", 234, 240], ["tracheal", "ANATOMY", 242, 250], ["sample", "ANATOMY", 268, 274], ["designBacterial co-infection", "DISEASE", 99, 127], ["infection", "DISEASE", 334, 343], ["patients", "ORGANISM", 143, 151], ["blood", "ORGANISM_SUBSTANCE", 196, 201], ["pleural fluid", "ORGANISM_SUBSTANCE", 219, 232], ["sputum", "ORGANISM_SUBSTANCE", 234, 240], ["tracheal", "ORGAN", 242, 250], ["patients", "SPECIES", 143, 151], ["Study designBacterial co-infection", "PROBLEM", 93, 127], ["a blood culture", "TEST", 194, 209], ["a pleural fluid", "TEST", 217, 232], ["sputum", "TEST", 234, 240], ["tracheal or bronchoscopic sample", "PROBLEM", 242, 274], ["the isolate", "PROBLEM", 278, 289], ["a pathogen", "PROBLEM", 294, 304], ["a true infection", "PROBLEM", 327, 343], ["co-infection", "OBSERVATION", 115, 127], ["pleural", "ANATOMY", 219, 226], ["fluid", "OBSERVATION", 227, 232], ["tracheal", "ANATOMY", 242, 250], ["true", "OBSERVATION_MODIFIER", 329, 333], ["infection", "OBSERVATION", 334, 343]]], ["Viral co-infection was defined in patients having a positive PCR or appropriate antibody test for a viral pathogen other than influenza.", [["Viral co-infection", "DISEASE", 0, 18], ["influenza", "DISEASE", 126, 135], ["Viral", "ORGANISM", 0, 5], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["Viral co-infection", "PROBLEM", 0, 18], ["a positive PCR", "PROBLEM", 50, 64], ["appropriate antibody test", "TEST", 68, 93], ["a viral pathogen", "PROBLEM", 98, 114], ["influenza", "PROBLEM", 126, 135], ["co-infection", "OBSERVATION", 6, 18]]], ["Bacterial co-infections cultured within 48 h of hospital admission were defined as community-acquired; those cultured after 48 h were considered to be hospital-acquired.", [["Bacterial co-infections", "PROBLEM", 0, 23], ["co-infections", "OBSERVATION", 10, 23]]], ["Bacterial identification and susceptibility testing were performed by methods determined by institutional guidelines.", [["Bacterial identification", "TEST", 0, 24], ["susceptibility testing", "TEST", 29, 51]]], ["For all patients, management was according to institutional practices.Statistical analysis ::: Study designSTATA v12 (College Station, TX: StataCorp LP) was used for all analyses.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["management", "TREATMENT", 18, 28], ["TX: StataCorp LP)", "TREATMENT", 135, 152]]], ["Outliers were reexamined in the EHR to ensure data accuracy.", [["data accuracy", "TEST", 46, 59]]], ["No subject with outlying values was excluded from any analysis.", [["any analysis", "TEST", 50, 62]]], ["Bivariable analyses were used to compare potential risk factors for bacterial co-infection diagnosed during the 30 days after ICU admission or present on admission.", [["bacterial co-infection", "DISEASE", 68, 90], ["Bivariable analyses", "TEST", 0, 19], ["bacterial co-infection", "PROBLEM", 68, 90], ["co-infection", "OBSERVATION", 78, 90]]], ["A multivariable logistic regression model was developed to determine which of the variables significantly associated in bivariable analyses (p < 0.05) were independently associated with co-infection.", [["co-infection", "DISEASE", 186, 198], ["A multivariable logistic regression model", "PROBLEM", 0, 41], ["co-infection", "PROBLEM", 186, 198], ["co-infection", "OBSERVATION", 186, 198]]], ["Further multivariable analysis was used to predict risk of death among co-infected patients and also to assess resource utilization accounting for admission SOFA score.ResultsFive hundred and seven patients with severe influenza were admitted to ICUs at one of the 33 U.S. hospitals participating in the SHIC study in 2013\u20132014.", [["death", "DISEASE", 59, 64], ["influenza", "DISEASE", 219, 228], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 198, 206], ["Further multivariable analysis", "TEST", 0, 30], ["death", "PROBLEM", 59, 64], ["SOFA score", "TEST", 157, 167], ["severe influenza", "PROBLEM", 212, 228], ["the SHIC study", "TEST", 300, 314], ["severe", "OBSERVATION_MODIFIER", 212, 218], ["influenza", "OBSERVATION", 219, 228]]], ["In this cohort influenza A (H1N1) pdm09 caused 311 (61.3%) infections, and influenza A virus that were not subtyped caused 170 (33.5%) additional infections.", [["influenza A (H1N1) pdm09", "DISEASE", 15, 39], ["infections", "DISEASE", 59, 69], ["influenza A virus", "DISEASE", 75, 92], ["infections", "DISEASE", 146, 156], ["influenza A (H1N1) pdm09", "ORGANISM", 15, 39], ["influenza A virus", "ORGANISM", 75, 92], ["influenza A (H1N1", "SPECIES", 15, 32], ["influenza A virus", "SPECIES", 75, 92], ["influenza A virus", "SPECIES", 75, 92], ["pdm09", "PROBLEM", 34, 39], ["infections", "PROBLEM", 59, 69], ["influenza A virus", "PROBLEM", 75, 92], ["additional infections", "PROBLEM", 135, 156], ["infections", "OBSERVATION", 146, 156]]], ["Other influenza strains caused 5.2% of infections (Table 1).ResultsThere were 444 adult and 63 pediatric subjects.", [["influenza", "DISEASE", 6, 15], ["infections", "DISEASE", 39, 49], ["Other influenza strains", "PROBLEM", 0, 23], ["infections", "PROBLEM", 39, 49], ["infections", "OBSERVATION", 39, 49]]], ["Bacterial co-infection was present in 114 (22.5%) subjects, comprising 23.2% of adult and 17.5% of pediatric subjects.", [["Bacterial co-infection", "DISEASE", 0, 22], ["Bacterial co-infection", "PROBLEM", 0, 22], ["co-infection", "OBSERVATION", 10, 22]]], ["Sixty two (12.2%) subjects developed community-acquired bacterial co-infection and 52 (10.3%) subjects developed hospital-acquired bacterial co-infection.", [["bacterial co-infection", "DISEASE", 56, 78], ["bacterial co-infection", "DISEASE", 131, 153], ["community-acquired bacterial co-infection", "PROBLEM", 37, 78], ["hospital-acquired bacterial co-infection", "PROBLEM", 113, 153], ["bacterial co-infection", "OBSERVATION", 56, 78], ["bacterial co-infection", "OBSERVATION", 131, 153]]], ["Of the patients who developed community-acquired and hospital-acquired bacterial co-infections, 15/62 (24.2%) and 14/52 (26.9%), respectively, had no significant comorbid conditions.ResultsThere were 129 total bacterial isolates cultured from the 507 patients in our cohort (Table 2), including 26 (20.2%) methicillin resistant S. aureus (MRSA), 21 (16.3%) methicillin susceptible S. aureus (MSSA), 20 (15.5%) Enterobacteriaceae species, 18 (14.0%) Pseudomonas species, 7 (5.4%) S. pneumoniae and 37 (28.7%) other species (Table 2).", [["bacterial co-infections", "DISEASE", 71, 94], ["methicillin", "CHEMICAL", 306, 317], ["S. aureus (MRSA)", "DISEASE", 328, 344], ["methicillin", "CHEMICAL", 357, 368], ["MSSA", "CHEMICAL", 392, 396], ["methicillin", "CHEMICAL", 306, 317], ["methicillin", "CHEMICAL", 357, 368], ["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 251, 259], ["methicillin resistant S. aureus", "ORGANISM", 306, 337], ["MRSA", "CANCER", 339, 343], ["methicillin susceptible", "ORGANISM", 357, 380], ["S. aureus", "ORGANISM", 381, 390], ["MSSA", "CANCER", 392, 396], ["S. pneumoniae", "ORGANISM", 479, 492], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 251, 259], ["S. aureus", "SPECIES", 328, 337], ["MRSA", "SPECIES", 339, 343], ["S. aureus", "SPECIES", 381, 390], ["S. pneumoniae", "SPECIES", 479, 492], ["S. aureus", "SPECIES", 328, 337], ["MRSA", "SPECIES", 339, 343], ["S. aureus", "SPECIES", 381, 390], ["MSSA", "SPECIES", 392, 396], ["S. pneumoniae", "SPECIES", 479, 492], ["acquired bacterial co-infections", "PROBLEM", 62, 94], ["significant comorbid conditions", "PROBLEM", 150, 181], ["total bacterial isolates", "TEST", 204, 228], ["methicillin resistant S. aureus (MRSA", "PROBLEM", 306, 343], ["methicillin susceptible S. aureus (MSSA)", "PROBLEM", 357, 397], ["Enterobacteriaceae species", "TEST", 410, 436], ["Pseudomonas species", "TEST", 449, 468], ["S. pneumoniae", "TEST", 479, 492], ["bacterial co-infections", "OBSERVATION", 71, 94], ["no", "UNCERTAINTY", 147, 149], ["significant", "OBSERVATION_MODIFIER", 150, 161], ["comorbid conditions", "OBSERVATION", 162, 181], ["aureus", "OBSERVATION", 331, 337], ["aureus", "OBSERVATION", 384, 390], ["pneumoniae", "OBSERVATION", 482, 492]]], ["S. aureus susceptibilities are displayed in Fig. 1.", [["S. aureus", "ORGANISM", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus susceptibilities", "PROBLEM", 0, 26], ["aureus", "OBSERVATION", 3, 9]]], ["Of the MRSA isolates, all were susceptible to trimethoprim-sulfamethoxazole, 96.2% to tetracycline, 56% to clindamycin and 20.8% to erythromycin.Results", [["trimethoprim-sulfamethoxazole", "CHEMICAL", 46, 75], ["tetracycline", "CHEMICAL", 86, 98], ["clindamycin", "CHEMICAL", 107, 118], ["erythromycin", "CHEMICAL", 132, 144], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 46, 75], ["tetracycline", "CHEMICAL", 86, 98], ["clindamycin", "CHEMICAL", 107, 118], ["erythromycin", "CHEMICAL", 132, 144], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 46, 75], ["tetracycline", "SIMPLE_CHEMICAL", 86, 98], ["clindamycin", "SIMPLE_CHEMICAL", 107, 118], ["erythromycin", "SIMPLE_CHEMICAL", 132, 144], ["MRSA", "SPECIES", 7, 11], ["MRSA", "SPECIES", 7, 11], ["the MRSA isolates", "PROBLEM", 3, 20], ["trimethoprim", "TREATMENT", 46, 58], ["sulfamethoxazole", "TREATMENT", 59, 75], ["tetracycline", "TREATMENT", 86, 98], ["clindamycin", "TREATMENT", 107, 118], ["erythromycin", "TREATMENT", 132, 144]]]], "681ac12d3d0dfeee2340bd0ffe1b9129bb58fdf5": [["IntroductionThe COVID-19 crises can be stated to have redefined the three pillars of sustainability adding a fourth pillar 'Human Health' to its very concept [12] .", [["Human", "ORGANISM", 124, 129], ["Human", "SPECIES", 124, 129], ["The COVID-19 crises", "TREATMENT", 12, 31], ["a fourth pillar 'Human Health'", "TREATMENT", 107, 137]]], ["In December 2019, the health authorities in Wuhan, China received the first information on tens of patients with unknown cause for pneumonia symptoms.", [["pneumonia", "DISEASE", 131, 140], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["pneumonia symptoms", "PROBLEM", 131, 149], ["pneumonia", "OBSERVATION", 131, 140]]], ["The first case of novel coronavirus outside of China was confirmed January 13th [38] .", [["coronavirus", "ORGANISM", 24, 35], ["novel coronavirus", "PROBLEM", 18, 35]]], ["Ever since then, the world has faced an evolving wave of coronavirus disease, COVID-19, and as of August 23, 2020, over 23,574,130 confirmed cases with 812,104 deaths have been reported globally [40] .", [["coronavirus disease", "DISEASE", 57, 76], ["deaths", "DISEASE", 160, 166], ["coronavirus", "ORGANISM", 57, 68], ["coronavirus disease", "PROBLEM", 57, 76], ["COVID", "TEST", 78, 83], ["coronavirus disease", "OBSERVATION", 57, 76]]], ["As viruses and diseases often have different names, this virus is called severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 [38] .", [["acute respiratory syndrome coronavirus", "DISEASE", 80, 118], ["SARS-CoV-2", "ORGANISM", 124, 134], ["severe acute respiratory syndrome coronavirus", "SPECIES", 73, 118], ["SARS-CoV", "SPECIES", 124, 132], ["diseases", "PROBLEM", 15, 23], ["this virus", "PROBLEM", 52, 62], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 73, 118], ["SARS", "PROBLEM", 124, 128], ["CoV", "TEST", 129, 132], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["respiratory syndrome", "OBSERVATION", 86, 106]]], ["The public perception of the novel virus is can be considered even mysterious, and it has created a lot of concern on its transmissibility including its stability on surfaces and transmission through air.", [["the novel virus", "PROBLEM", 25, 40], ["virus", "OBSERVATION", 35, 40], ["stability", "OBSERVATION_MODIFIER", 153, 162], ["air", "OBSERVATION", 200, 203]]], ["From an individual perspective, concrete protective action items including use of surgical and N95 masks, bandanas, and gloves have become an everyday discussion topic.", [["surgical and N95 masks", "TREATMENT", 82, 104], ["bandanas", "TREATMENT", 106, 114], ["gloves", "TREATMENT", 120, 126]]], ["The uncertainty in protective measures and actions is partially due to the limited information and research available on coronavirus transmittance and survival.", [["coronavirus", "ORGANISM", 121, 132], ["protective measures", "TREATMENT", 19, 38], ["coronavirus transmittance", "TREATMENT", 121, 146]]], ["This clearly increases public uncertainty and fear.", [["increases", "OBSERVATION_MODIFIER", 13, 22], ["public uncertainty", "OBSERVATION", 23, 41]]], ["In this review, the current understanding on SARS-CoV-2 transmittance risks from fomite-to-human was critically assessed with the specific focus on the global supply chain in connection to parcel shipments and specifically fiber-based packaging.", [["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["fiber-based packaging", "TREATMENT", 223, 244]]], ["The consumer-faced viral contamination and transmittance risks related to packaging are also discussed reflecting on the existing and available research results.Global Trade and Supply ChainThe role of shipments of letters and parcels in the global security risks on transmittance of biological and chemical threats is not new.", [["faced viral contamination", "PROBLEM", 13, 38], ["transmittance risks", "PROBLEM", 43, 62], ["packaging", "TREATMENT", 74, 83], ["viral contamination", "OBSERVATION", 19, 38], ["Trade", "OBSERVATION", 168, 173], ["Chain", "OBSERVATION_MODIFIER", 185, 190], ["new", "OBSERVATION_MODIFIER", 323, 326]]], ["Last wave of concern was during the 2001 anthrax attacks [7] .", [["anthrax", "DISEASE", 41, 48]]], ["Most remarkably, letters containing Bacillus anthracis were sent to political figures raising national and international concerns of the safety of the postal service and the entire parcel shipping system.", [["Bacillus anthracis", "ORGANISM", 36, 54], ["Bacillus anthracis", "SPECIES", 36, 54], ["Bacillus anthracis", "SPECIES", 36, 54], ["Bacillus anthracis", "PROBLEM", 36, 54]]], ["These concerns have perhaps been less in public media, but certainly considered by the national agencies such as US CDC (Centers for Disease Control and Prevention) and other agencies working on national security.Global Trade and Supply ChainThe biohazards and related risks in the shipping and postal service system are increasing as consumers have become more and more reliant on these services.", [["Disease Control", "TREATMENT", 133, 148], ["postal service system", "TREATMENT", 295, 316], ["less", "OBSERVATION_MODIFIER", 33, 37], ["Trade", "OBSERVATION", 220, 225], ["Chain", "OBSERVATION_MODIFIER", 237, 242]]], ["Globalization and the growth of trade and shipping have grown the parcel shipping quantities to a staggering number of more than 90bn in parcel volume globally.", [["growth", "OBSERVATION_MODIFIER", 22, 28], ["trade", "OBSERVATION_MODIFIER", 32, 37], ["grown", "OBSERVATION_MODIFIER", 56, 61], ["parcel shipping", "OBSERVATION", 66, 81], ["staggering", "OBSERVATION_MODIFIER", 98, 108], ["number", "OBSERVATION_MODIFIER", 109, 115]]], ["The estimated global shipping volumes reaching $200bn in 2025 and the parcel shipping revenues have increased to more than $300bn [24] .", [["The estimated global shipping volumes", "PROBLEM", 0, 37], ["global", "OBSERVATION_MODIFIER", 14, 20], ["shipping", "OBSERVATION_MODIFIER", 21, 29], ["volumes", "OBSERVATION_MODIFIER", 30, 37], ["increased", "OBSERVATION_MODIFIER", 100, 109]]], ["The related supply chains have also faced major changes in the way they operate.", [["The related supply chains", "TREATMENT", 0, 25], ["supply chains", "OBSERVATION", 12, 25]]], ["For example, the traditional approach was to transport bulk products to brick-and-mortar retail stores or distribution centers that then could handle smaller volumes of direct-to-consumer catalog orders.", [["transport bulk products", "TREATMENT", 45, 68]]], ["Major change occurred when a rapid development of e-commerce enabling infrastructure took place.", [["Major change", "PROBLEM", 0, 12]]], ["This included electronic funds transfer, Internet marketing, online transactions processing, electronic data interchange (EDI), and inventory management systems.", [["inventory management systems", "TREATMENT", 132, 160]]], ["Within the traditional system, the market was more characterized by scarcity and ensuring essential availability of products.Global Trade and Supply ChainThe modern e-commerce requires more and the need to maintain inventory has reduced dramatically.", [["scarcity", "OBSERVATION", 68, 76], ["Trade", "OBSERVATION", 132, 137], ["Chain", "OBSERVATION_MODIFIER", 149, 154]]], ["The new supply chain model also has to meet the changing needs of the consumer using the power of the big data analytics and the Internet of things and to leverage artificial intelligence capabilities.", [["new", "OBSERVATION_MODIFIER", 4, 7], ["supply", "OBSERVATION_MODIFIER", 8, 14], ["chain model", "OBSERVATION", 15, 26]]], ["The growth in e-commerce creates expectations to deliver goods inexpensively and, promptly, the retailers have established dedicated dot-com fulfillment centers, which then service the end customer via UPS, the DHL international, or any national postal services in question.", [["growth", "OBSERVATION_MODIFIER", 4, 10]]], ["Some larger e-commerce companies can orchestrate inbound freight moving into one of the regional distribution centers with shipments and then moved to customers, for example, via private fleet.", [["larger", "OBSERVATION_MODIFIER", 5, 11], ["e-commerce", "OBSERVATION", 12, 22]]], ["These changes in global trade and parcel shipping are critical to understand when analyzing biological threats and SARS-CoV-2 transmittance.Global Trade and Supply ChainRecent studies show that the SARS-CoV-2 virus is highly contagious and has an unusual long surface stability [22, 32] .", [["surface", "ANATOMY", 260, 267], ["SARS", "DISEASE", 115, 119], ["SARS", "DISEASE", 198, 202], ["SARS-CoV-2 virus", "ORGANISM", 198, 214], ["SARS-CoV-2 virus", "SPECIES", 198, 214], ["Supply ChainRecent studies", "TEST", 157, 183], ["the SARS-CoV-2 virus", "PROBLEM", 194, 214], ["global", "OBSERVATION_MODIFIER", 17, 23], ["trade", "OBSERVATION_MODIFIER", 24, 29], ["parcel shipping", "OBSERVATION", 34, 49], ["contagious", "OBSERVATION_MODIFIER", 225, 235], ["unusual", "OBSERVATION_MODIFIER", 247, 254], ["long", "OBSERVATION_MODIFIER", 255, 259], ["surface", "OBSERVATION_MODIFIER", 260, 267], ["stability", "OBSERVATION_MODIFIER", 268, 277]]], ["This creates significant risks and concerns from the global trade perspective.", [["significant", "OBSERVATION_MODIFIER", 13, 24]]], ["The parcel shipments from globally contaminated areas are fast and the storage time in warehouses mainly does not exist.", [["globally contaminated areas", "PROBLEM", 26, 53], ["parcel shipments", "OBSERVATION", 4, 20], ["globally", "OBSERVATION_MODIFIER", 26, 34], ["contaminated", "OBSERVATION_MODIFIER", 35, 47], ["areas", "OBSERVATION_MODIFIER", 48, 53]]], ["The shipped goods may potentially have surfaces where SARS-CoV-2 virus survives the whole duration of the shipment and transmits to the supply chain workers and ultimately the consumer.", [["SARS", "DISEASE", 54, 58], ["SARS-CoV-2 virus", "ORGANISM", 54, 70], ["SARS-CoV-2 virus", "SPECIES", 54, 70], ["SARS", "PROBLEM", 54, 58], ["CoV", "PROBLEM", 59, 62], ["2 virus", "PROBLEM", 63, 70], ["surfaces", "OBSERVATION_MODIFIER", 39, 47]]], ["This risk is becoming more and more imminent and a public concern as the COVID-19 pandemic continues.Role of PackagingThere are different packing materials that are used in global trade.", [["the COVID", "TEST", 69, 78], ["pandemic", "PROBLEM", 82, 90], ["Packaging", "TREATMENT", 109, 118], ["different packing materials", "TREATMENT", 128, 155], ["Packaging", "OBSERVATION", 109, 118], ["different", "OBSERVATION_MODIFIER", 128, 137], ["packing materials", "OBSERVATION", 138, 155]]], ["The materials used in commercial packaging include plastics, aluminum, cardboard, glass, and foam.", [["aluminum", "CHEMICAL", 61, 69], ["aluminum", "CHEMICAL", 61, 69], ["aluminum", "SIMPLE_CHEMICAL", 61, 69], ["The materials", "TREATMENT", 0, 13], ["commercial packaging", "TREATMENT", 22, 42], ["plastics, aluminum, cardboard, glass", "TREATMENT", 51, 87], ["foam", "TREATMENT", 93, 97]]], ["Although the shipping trends have been towards smaller packing for transportation efficiency gains, plastic or flexible packaging has not successfully replaced cardboard as the main packaging material.", [["transportation efficiency gains", "TREATMENT", 67, 98], ["plastic or flexible packaging", "TREATMENT", 100, 129], ["smaller", "OBSERVATION_MODIFIER", 47, 54], ["packing", "OBSERVATION_MODIFIER", 55, 62], ["main", "OBSERVATION_MODIFIER", 177, 181], ["packaging material", "OBSERVATION", 182, 200]]], ["The main surface a consumer gets exposed to in home deliveries is the cardboard box or also called corrugated box.", [["surface", "ANATOMY", 9, 16], ["cardboard box", "DNA", 70, 83], ["corrugated box", "DNA", 99, 113], ["main", "OBSERVATION_MODIFIER", 4, 8], ["surface", "OBSERVATION_MODIFIER", 9, 16]]], ["This type of material is used in smaller parcel boxes and larger shipping boxes.", [["parcel boxes", "DNA", 41, 53], ["shipping boxes", "DNA", 65, 79], ["larger shipping boxes", "TREATMENT", 58, 79], ["smaller", "OBSERVATION_MODIFIER", 33, 40], ["parcel boxes", "OBSERVATION", 41, 53], ["larger", "OBSERVATION_MODIFIER", 58, 64], ["shipping boxes", "OBSERVATION", 65, 79]]], ["The material surface (secondary packaging) that the consumer or supply chain worker is exposed to is fiber-based linerboard which is mainly made of softwood (pine tree or pinus) pulp or more specifically unbleached softwood kraft with long and strong ligno-cellulosic fibers that bond well and give ideal strength to the box.", [["surface", "ANATOMY", 13, 20], ["pinus", "ANATOMY", 171, 176], ["pulp", "ANATOMY", 178, 182], ["tree", "ORGANISM_SUBDIVISION", 163, 167], ["pulp", "TISSUE", 178, 182], ["The material surface (secondary packaging", "TREATMENT", 0, 41], ["softwood (pine tree or pinus) pulp", "PROBLEM", 148, 182], ["strong ligno-cellulosic fibers", "TREATMENT", 244, 274], ["material", "OBSERVATION_MODIFIER", 4, 12], ["surface", "OBSERVATION_MODIFIER", 13, 20], ["pine tree", "OBSERVATION", 158, 167], ["pinus", "OBSERVATION_MODIFIER", 171, 176], ["pulp", "ANATOMY", 178, 182], ["softwood kraft", "OBSERVATION", 215, 229], ["cellulosic fibers", "OBSERVATION", 257, 274]]], ["Often OCC (Old Corrugated Container) recycled pulp is also used for the surface material of the cardboard boxes reducing the cost and increasing the sustainability and recycling aspects of the boxes.", [["pulp", "ANATOMY", 46, 50], ["surface", "ANATOMY", 72, 79], ["pulp", "TISSUE", 46, 50], ["Old Corrugated Container) recycled pulp", "TREATMENT", 11, 50], ["the surface material", "TREATMENT", 68, 88], ["the cardboard boxes", "TREATMENT", 92, 111], ["pulp", "ANATOMY", 46, 50]]], ["The other fiber-based packaging types (primary packaging) include paperboard which is a paper-based material that is lightweight, yet strong.", [["The other fiber-based packaging types (primary packaging", "TREATMENT", 0, 56], ["fiber", "OBSERVATION_MODIFIER", 10, 15], ["packaging types", "OBSERVATION", 22, 37], ["strong", "OBSERVATION_MODIFIER", 134, 140]]], ["This material comes in various grades, each suitable for different packaging requirements.", [["different packaging requirements", "TREATMENT", 57, 89], ["packaging requirements", "OBSERVATION", 67, 89]]], ["This type of fiber-based packaging includes WLC (White-lined Chipboard), typically made from layers of recycled fibers, SBS (solid bleached sulfate) carton, CUK (coated unbleached kraft) carton or FBB (folding box board) carton that is considered the most sustainable and made from several layers of chemical and mechanical pulp.", [["fibers", "ANATOMY", 112, 118], ["pulp", "ANATOMY", 324, 328], ["carton", "CHEMICAL", 149, 155], ["CUK", "CHEMICAL", 157, 160], ["FBB", "CHEMICAL", 197, 200], ["sulfate", "CHEMICAL", 140, 147], ["CUK", "CHEMICAL", 157, 160], ["fibers", "TISSUE", 112, 118], ["sulfate", "SIMPLE_CHEMICAL", 140, 147], ["carton", "SIMPLE_CHEMICAL", 149, 155], ["CUK", "SIMPLE_CHEMICAL", 157, 160], ["FBB", "SIMPLE_CHEMICAL", 197, 200], ["pulp", "TISSUE", 324, 328], ["fiber-based packaging", "TREATMENT", 13, 34], ["WLC (White-lined Chipboard", "TREATMENT", 44, 70], ["SBS (solid bleached sulfate) carton", "TREATMENT", 120, 155], ["CUK (coated unbleached kraft)", "TREATMENT", 157, 186], ["FBB (folding box board", "TREATMENT", 197, 219], ["chemical and mechanical pulp", "TREATMENT", 300, 328], ["recycled fibers", "OBSERVATION", 103, 118], ["mechanical pulp", "OBSERVATION", 313, 328]]], ["In addition, a rigid box which is made of a highly condensed paperboard (even four times thicker than FBB or SBS carton) is used for boxes that hold for example Apple's iPhones and iPads.", [["iPads", "SIMPLE_CHEMICAL", 181, 186], ["iPads", "PROTEIN", 181, 186], ["a rigid box", "TREATMENT", 13, 24], ["a highly condensed paperboard", "PROBLEM", 42, 71], ["SBS carton", "TREATMENT", 109, 119], ["iPads", "TREATMENT", 181, 186], ["rigid box", "OBSERVATION", 15, 24], ["highly", "OBSERVATION_MODIFIER", 44, 50], ["condensed", "OBSERVATION", 51, 60]]], ["For the surface stability of SARS-CoV-2, it is important to understand that these carton types may be coated with a mixture of materials including polymers.", [["surface", "ANATOMY", 8, 15], ["SARS", "DISEASE", 29, 33], ["SARS", "PROBLEM", 29, 33], ["these carton types", "TREATMENT", 76, 94], ["a mixture of materials", "TREATMENT", 114, 136], ["polymers", "TREATMENT", 147, 155], ["SARS", "OBSERVATION", 29, 33]]], ["The coatings are used to impart certain qualities to the carton, including haptics such as smoothness and grip and weight, surface gloss, or ink absorbency.", [["surface", "ANATOMY", 123, 130], ["The coatings", "TREATMENT", 0, 12], ["haptics", "TREATMENT", 75, 82], ["grip", "TEST", 106, 110], ["weight", "TEST", 115, 121], ["ink absorbency", "PROBLEM", 141, 155]]], ["There are various materials that are used including kaoline, calcium carbonate, bentonite, and talc.", [["kaoline", "CHEMICAL", 52, 59], ["calcium carbonate", "CHEMICAL", 61, 78], ["bentonite", "CHEMICAL", 80, 89], ["talc", "CHEMICAL", 95, 99], ["kaoline", "CHEMICAL", 52, 59], ["calcium carbonate", "CHEMICAL", 61, 78], ["bentonite", "CHEMICAL", 80, 89], ["talc", "CHEMICAL", 95, 99], ["kaoline", "SIMPLE_CHEMICAL", 52, 59], ["calcium carbonate", "SIMPLE_CHEMICAL", 61, 78], ["bentonite", "SIMPLE_CHEMICAL", 80, 89], ["various materials", "TREATMENT", 10, 27], ["kaoline", "TREATMENT", 52, 59], ["calcium carbonate", "TREATMENT", 61, 78], ["bentonite", "TREATMENT", 80, 89], ["talc", "TREATMENT", 95, 99], ["various materials", "OBSERVATION", 10, 27], ["talc", "OBSERVATION", 95, 99]]], ["From polymer side, styrene acrylic and acrylic polymer emulsions, styrene-butadiene latex, or carboxylated styrenebutadiene emulsions can be used, all of them designed to accept ink, create gloss, and form a barrier to grease and moisture.", [["styrene acrylic", "CHEMICAL", 19, 34], ["acrylic polymer emulsions", "CHEMICAL", 39, 64], ["styrene-butadiene", "CHEMICAL", 66, 83], ["carboxylated styrenebutadiene", "CHEMICAL", 94, 123], ["styrene acrylic", "CHEMICAL", 19, 34], ["styrene", "CHEMICAL", 66, 73], ["butadiene", "CHEMICAL", 74, 83], ["styrenebutadiene", "CHEMICAL", 107, 123], ["styrene acrylic", "SIMPLE_CHEMICAL", 19, 34], ["acrylic polymer emulsions", "SIMPLE_CHEMICAL", 39, 64], ["styrene-butadiene latex", "SIMPLE_CHEMICAL", 66, 89], ["carboxylated styrenebutadiene emulsions", "SIMPLE_CHEMICAL", 94, 133], ["styrene acrylic and acrylic polymer emulsions", "TREATMENT", 19, 64], ["styrene-butadiene latex", "TREATMENT", 66, 89], ["carboxylated styrenebutadiene emulsions", "TREATMENT", 94, 133], ["styrene acrylic", "OBSERVATION", 19, 34]]], ["The box material from a surface perspective can therefore be a complicated mix of several ceramic materials and polymers.", [["surface", "ANATOMY", 24, 31], ["several ceramic materials and polymers", "TREATMENT", 82, 120], ["ceramic materials", "OBSERVATION", 90, 107]]], ["All these various materials can potentially have a different viral surface stability and transmittance that the supply chain nor the consumer is aware off.Viral Stability and Transmittance on SurfacesWith severe acute respiratory syndrome (SARS) coronavirus and Middle East respiratory syndrome (MERS) coronavirus, the novel coronavirus SARS-CoV-2 is the third highly pathogenic human coronavirus that has emerged within the last 2 decades [10] .", [["surface", "ANATOMY", 67, 74], ["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 212, 257], ["Middle East respiratory syndrome (MERS) coronavirus", "DISEASE", 262, 313], ["SARS", "DISEASE", 337, 341], ["Middle East respiratory", "ORGANISM", 262, 285], ["coronavirus SARS-CoV-2", "ORGANISM", 325, 347], ["human", "ORGANISM", 379, 384], ["coronavirus", "SPECIES", 246, 257], ["coronavirus SARS-CoV", "SPECIES", 325, 345], ["human", "SPECIES", 379, 384], ["coronavirus", "SPECIES", 385, 396], ["SurfacesWith severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 192, 257], ["Middle East respiratory syndrome (MERS) coronavirus", "SPECIES", 262, 313], ["SARS-CoV-2", "SPECIES", 337, 347], ["human coronavirus", "SPECIES", 379, 396], ["a different viral surface stability", "PROBLEM", 49, 84], ["Viral Stability", "PROBLEM", 155, 170], ["Transmittance on SurfacesWith severe acute respiratory syndrome", "PROBLEM", 175, 238], ["SARS)", "PROBLEM", 240, 245], ["coronavirus", "PROBLEM", 246, 257], ["Middle East respiratory syndrome", "PROBLEM", 262, 294], ["coronavirus", "PROBLEM", 302, 313], ["the novel coronavirus SARS", "PROBLEM", 315, 341], ["the third highly pathogenic human coronavirus", "PROBLEM", 351, 396], ["different", "OBSERVATION_MODIFIER", 51, 60], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["surface stability", "OBSERVATION", 67, 84], ["Stability", "OBSERVATION", 161, 170], ["severe", "OBSERVATION_MODIFIER", 205, 211], ["acute", "OBSERVATION_MODIFIER", 212, 217], ["respiratory syndrome", "OBSERVATION", 218, 238], ["Middle", "ANATOMY_MODIFIER", 262, 268], ["respiratory syndrome", "OBSERVATION", 274, 294], ["human coronavirus", "OBSERVATION", 379, 396]]], ["Although MERS-CoV and SARS-CoV-1 resulted in deaths, neither had such global impact as SARS-CoV-2, resulting in the World Health Organization to declare it a global pandemic on March 11, 2020.", [["deaths", "DISEASE", 45, 51], ["MERS-CoV", "ORGANISM", 9, 17], ["SARS-CoV-1", "ORGANISM", 22, 32], ["MERS-CoV", "SPECIES", 9, 17], ["SARS-CoV-1", "SPECIES", 22, 32], ["SARS-CoV", "SPECIES", 87, 95], ["MERS", "PROBLEM", 9, 13], ["CoV", "PROBLEM", 14, 17], ["SARS", "PROBLEM", 22, 26]]], ["Since SARS-CoV-2 is novel, research on understanding its transmission from human-to-human and fomite-to-human is ongoing.", [["SARS", "DISEASE", 6, 10], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 6, 16], ["human", "ORGANISM", 75, 80], ["human", "ORGANISM", 84, 89], ["human", "ORGANISM", 104, 109], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 104, 109]]], ["However, investigations have been performed on other emerging coronaviruses, such as MERS, SARS, endemic human coronavirus strain HCoV, as well as veterinary coronaviruses, such as gastroenteritis virus (TGEV), mouse hepatitis virus (MHV), and canine coronavirus (CCV) giving an indication on SARS-CoV-2 stability on surfaces.", [["SARS", "DISEASE", 91, 95], ["veterinary coronaviruses", "DISEASE", 147, 171], ["gastroenteritis virus", "DISEASE", 181, 202], ["mouse hepatitis virus (MHV), and canine coronavirus", "DISEASE", 211, 262], ["coronaviruses", "ORGANISM", 62, 75], ["MERS", "GENE_OR_GENE_PRODUCT", 85, 89], ["human", "ORGANISM", 105, 110], ["coronavirus strain HCoV", "ORGANISM", 111, 134], ["veterinary coronaviruses", "ORGANISM", 147, 171], ["gastroenteritis virus", "ORGANISM", 181, 202], ["TGEV", "ORGANISM", 204, 208], ["mouse hepatitis virus", "ORGANISM", 211, 232], ["MHV", "ORGANISM", 234, 237], ["canine coronavirus", "ORGANISM", 244, 262], ["CCV", "ORGANISM", 264, 267], ["human", "SPECIES", 105, 110], ["coronavirus", "SPECIES", 111, 122], ["gastroenteritis virus", "SPECIES", 181, 202], ["TGEV", "SPECIES", 204, 208], ["mouse", "SPECIES", 211, 216], ["hepatitis virus", "SPECIES", 217, 232], ["canine coronavirus", "SPECIES", 244, 262], ["human coronavirus", "SPECIES", 105, 122], ["HCoV", "SPECIES", 130, 134], ["gastroenteritis virus", "SPECIES", 181, 202], ["TGEV", "SPECIES", 204, 208], ["mouse hepatitis virus", "SPECIES", 211, 232], ["MHV", "SPECIES", 234, 237], ["canine coronavirus", "SPECIES", 244, 262], ["CCV", "SPECIES", 264, 267], ["SARS-CoV", "SPECIES", 293, 301], ["SARS", "PROBLEM", 91, 95], ["endemic human coronavirus strain HCoV", "PROBLEM", 97, 134], ["veterinary coronaviruses", "PROBLEM", 147, 171], ["gastroenteritis virus", "PROBLEM", 181, 202], ["mouse hepatitis virus", "PROBLEM", 211, 232], ["canine coronavirus", "PROBLEM", 244, 262], ["SARS", "PROBLEM", 293, 297], ["CoV", "TEST", 298, 301]]], ["Most of the studies have concentrated more on hospital related surfaces, such as stainless steel, plastic, glass, gloves, and gowns.", [["the studies", "TEST", 8, 19], ["concentrated", "OBSERVATION_MODIFIER", 25, 37], ["stainless steel", "OBSERVATION_MODIFIER", 81, 96]]], ["In addition, most of the available research published has been on SARS-CoV-1.", [["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 66, 76], ["SARS-CoV-1", "SPECIES", 66, 76], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74]]], ["Indicatively, the survival and stability in case of SARS-CoV-1 can be exceptionally long as in plastics where it has been reported to persist at room temperature up to 6 days in suspension and 9 days in dried state [25] .", [["SARS", "DISEASE", 52, 56], ["SARS-CoV-1", "SPECIES", 52, 62], ["SARS", "PROBLEM", 52, 56], ["stability", "OBSERVATION_MODIFIER", 31, 40]]], ["Surprisingly, SARS-CoV-1 RNA was detected from carpet after 3 months an infected person had stayed at a hotel in Hong Kong [37] .", [["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 14, 24], ["SARS-CoV-1 RNA", "RNA", 14, 28], ["person", "SPECIES", 81, 87], ["SARS-CoV-1", "SPECIES", 14, 24], ["SARS", "PROBLEM", 14, 18]]], ["Although detection of RNA is not indicative of viability of the virus, it does suggest that the virus can survive longer periods of time when the material of the inanimate object can act as a protective barrier [9] .Viral Stability and Transmittance on SurfacesOnly a few investigations have specifically reported on the survival of coronaviruses on wood-and paper-related materials.", [["coronaviruses", "ORGANISM", 333, 346], ["RNA", "PROBLEM", 22, 25], ["viability of the virus", "PROBLEM", 47, 69], ["the virus", "PROBLEM", 92, 101], ["a protective barrier", "TREATMENT", 190, 210], ["coronaviruses", "PROBLEM", 333, 346], ["not indicative of", "UNCERTAINTY", 29, 46], ["virus", "OBSERVATION", 64, 69], ["Stability", "OBSERVATION", 222, 231]]], ["Lai reported that SARS-CoV-1 survived 24 h to less than 5 min on laboratory form paper depending on the viral titer of 10 6 TCID 50 /ml and 10 5 TCID 50 /ml, respectively [16] .", [["SARS", "DISEASE", 18, 22], ["SARS-CoV-1", "ORGANISM", 18, 28], ["SARS-CoV-1", "SPECIES", 18, 28], ["SARS", "PROBLEM", 18, 22], ["CoV", "TEST", 23, 26], ["the viral titer", "TEST", 100, 115]]], ["On the other hand, Duan [11] detected low levels of SARS-CoV-1 on wood board, press paper, and filter paper at room temperature even at 72, 96, and 120 h with initial viral concentration of 10 5 TCID 50 /ml.", [["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 52, 62], ["low levels of SARS", "PROBLEM", 38, 56], ["initial viral concentration", "TEST", 159, 186]]], ["As of now, only one study has been conducted on survival of SARS-CoV-2 on cardboard.", [["SARS", "DISEASE", 60, 64], ["SARS-CoV", "SPECIES", 60, 68], ["one study", "TEST", 16, 25], ["SARS", "TEST", 60, 64], ["CoV", "TEST", 65, 68]]], ["According to van Doremalen with an initial infectious titer of 10 3 TCID 50 /ml at 21\u02daC-23\u02daC and 40% relative humidity, SARS-CoV-2 survived longer than SARS-CoV-1 with no detection at 24 h versus 8 h [35] .", [["21\u02daC-23\u02daC", "CHEMICAL", 83, 92], ["SARS-CoV", "SPECIES", 120, 128], ["SARS-CoV-1", "SPECIES", 152, 162], ["SARS", "TEST", 120, 124], ["CoV", "TEST", 125, 128], ["CoV", "TEST", 157, 160]]], ["With 10 5 TCID 50 / ml, virus was inactivated within 1 h for cotton gowns rather than 24 h for disposable gowns [16] .", [["cotton", "SPECIES", 61, 67], ["virus", "TREATMENT", 24, 29], ["cotton gowns", "TREATMENT", 61, 73]]], ["Cotton contains natural fibers resulting in faster absorption of liquid than a disposable gown made of plastic components such as polypropylene and polyethylene.", [["fibers", "ANATOMY", 24, 30], ["Cotton", "CHEMICAL", 0, 6], ["polyethylene", "CHEMICAL", 148, 160], ["polypropylene", "CHEMICAL", 130, 143], ["polyethylene", "CHEMICAL", 148, 160], ["polypropylene", "SIMPLE_CHEMICAL", 130, 143], ["polyethylene", "SIMPLE_CHEMICAL", 148, 160], ["natural fibers", "TREATMENT", 16, 30], ["faster absorption of liquid", "PROBLEM", 44, 71], ["a disposable gown", "TREATMENT", 77, 94], ["plastic components", "TREATMENT", 103, 121], ["polypropylene", "TREATMENT", 130, 143], ["polyethylene", "TREATMENT", 148, 160], ["natural fibers", "OBSERVATION", 16, 30], ["faster", "OBSERVATION_MODIFIER", 44, 50], ["absorption", "OBSERVATION_MODIFIER", 51, 61], ["plastic components", "OBSERVATION_MODIFIER", 103, 121]]], ["Not only are the packaging surface components and the viral exposure titer important, but also temperature and relative humidity of the package delivery chain is crucial.", [["surface", "ANATOMY", 27, 34], ["the viral exposure titer", "PROBLEM", 50, 74], ["the package delivery chain", "TREATMENT", 132, 158], ["surface", "OBSERVATION_MODIFIER", 27, 34], ["components", "OBSERVATION_MODIFIER", 35, 45], ["viral exposure", "OBSERVATION", 54, 68]]], ["For example, dried SARS-CoV-1 on plastic surface survived up to 2 weeks in a typical air-conditioned environment (22-25 \u00b0C, 40-50% relative humidity), while at 38 \u00b0C with high relative humidity of > 95% had a faster effect on the viability [8] .", [["plastic surface", "ANATOMY", 33, 48], ["SARS-CoV-1", "CHEMICAL", 19, 29], ["SARS-CoV-1", "SPECIES", 19, 29], ["dried SARS", "PROBLEM", 13, 23]]], ["At 4 \u00b0C, veterinary coronaviruses MHV and TGEV in cell culture medium resembling human secretion survived up to 28 days at a range of 20-80% relative humidity on stainless steel (Casanova 2010) .", [["cell", "ANATOMY", 50, 54], ["coronaviruses MHV", "ORGANISM", 20, 37], ["TGEV", "ORGANISM", 42, 46], ["cell", "CELL", 50, 54], ["human", "ORGANISM", 81, 86], ["TGEV", "SPECIES", 42, 46], ["human", "SPECIES", 81, 86], ["MHV", "SPECIES", 34, 37], ["TGEV", "SPECIES", 42, 46], ["human", "SPECIES", 81, 86], ["veterinary coronaviruses MHV", "TREATMENT", 9, 37], ["TGEV in cell culture", "TEST", 42, 62], ["human secretion", "PROBLEM", 81, 96], ["stainless steel (Casanova", "TREATMENT", 162, 187], ["coronaviruses MHV", "OBSERVATION", 20, 37]]], ["Interestingly, heat treatment of 90 min at 56 \u00b0C or 30-45 min at 75 \u00b0-C with or without the presence of 20% protein additive FCS (fetal calf serum) completely inactivates the virus [9, 11, 25] .Mitigation of RisksThere are several approaches in developing effective antibacterial and antiviral solutions to various surfaces [3, 17, 30, 41] .", [["fetal calf serum", "ANATOMY", 130, 146], ["FCS", "ORGANISM_SUBSTANCE", 125, 128], ["fetal calf", "ORGANISM_SUBSTANCE", 130, 140], ["serum", "ORGANISM_SUBSTANCE", 141, 146], ["calf", "SPECIES", 136, 140], ["heat treatment", "TREATMENT", 15, 29], ["20% protein additive FCS", "TREATMENT", 104, 128], ["fetal calf serum", "TEST", 130, 146], ["the virus", "PROBLEM", 171, 180], ["effective antibacterial and antiviral solutions", "TREATMENT", 256, 303], ["calf", "ANATOMY", 136, 140], ["effective", "OBSERVATION_MODIFIER", 256, 265], ["antibacterial", "OBSERVATION", 266, 279]]], ["However, most of the solutions are aiming at a system that kills or inhibits the growth of microorganisms and with a purpose of extending the shelf life of food products that are perishable and, thus, to enhance the safety of packaged products [1, 13, 22, 26] .", [["the growth of microorganisms", "PROBLEM", 77, 105], ["growth", "OBSERVATION_MODIFIER", 81, 87]]], ["Many of these well-researched alternatives are also bacteria and virus specific which reduces the applicability in a broader scale.", [["bacteria", "PROBLEM", 52, 60], ["virus", "PROBLEM", 65, 70], ["a broader scale", "TREATMENT", 115, 130]]], ["If the solution has to be tailor-made for each viral threat, the adaptability for the whole supply chain will be highly challenging.", [["each viral threat", "PROBLEM", 42, 59], ["the whole supply chain", "TREATMENT", 82, 104]]], ["For the purpose of viral transmittance, suppressions, and mitigations, the packaging surface may demand hybrid surface structures with different layers of antiviral and bacterial performance and specificity.", [["surface", "ANATOMY", 85, 92], ["surface structures", "ANATOMY", 111, 129], ["viral transmittance", "TREATMENT", 19, 38], ["mitigations", "TREATMENT", 58, 69], ["the packaging surface", "TREATMENT", 71, 92], ["bacterial performance", "TEST", 169, 190], ["viral transmittance", "OBSERVATION", 19, 38], ["hybrid surface", "OBSERVATION", 104, 118], ["different", "OBSERVATION_MODIFIER", 135, 144], ["layers", "OBSERVATION_MODIFIER", 145, 151], ["antiviral", "OBSERVATION_MODIFIER", 155, 164]]], ["Especially in the case of fiber-based packaging, as earlier indicated, the surface of the package can be porous and absorbent.", [["surface", "ANATOMY", 75, 82], ["surface", "CELLULAR_COMPONENT", 75, 82], ["fiber-based packaging", "TREATMENT", 26, 47]]], ["At first, this may seem to be beneficial for the reduced risk on immediate human contact; however, it may also create an additional risk if a virus such as SARS-CoV-2 has exceptionally long survival rates [4, 16, 27, 28, 31, 34] .", [["SARS", "DISEASE", 156, 160], ["human", "ORGANISM", 75, 80], ["SARS-CoV-2", "ORGANISM", 156, 166], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["SARS-CoV", "SPECIES", 156, 164], ["a virus", "PROBLEM", 140, 147], ["SARS", "PROBLEM", 156, 160], ["CoV", "TEST", 161, 164]]], ["This photodynamic therapy (PDT) approach was also proven to inactivate several viruses including for example dengue-1 virus, influenza A, and human adenovirus-5.", [["dengue", "DISEASE", 109, 115], ["influenza A", "DISEASE", 125, 136], ["dengue-1 virus", "ORGANISM", 109, 123], ["influenza A", "ORGANISM", 125, 136], ["human", "ORGANISM", 142, 147], ["adenovirus-5", "ORGANISM", 148, 160], ["dengue-1 virus", "SPECIES", 109, 123], ["human", "SPECIES", 142, 147], ["dengue-1 virus", "SPECIES", 109, 123], ["influenza A", "SPECIES", 125, 136], ["human adenovirus-5", "SPECIES", 142, 160], ["This photodynamic therapy (PDT) approach", "TREATMENT", 0, 40], ["several viruses", "PROBLEM", 71, 86], ["example dengue-1 virus", "PROBLEM", 101, 123], ["influenza A", "PROBLEM", 125, 136], ["human adenovirus", "PROBLEM", 142, 158]]], ["This research demonstrated the potential of cellulose materials to serve as anti-infective or self-sterilizing materials against both bacteria and viruses [5, 36] .", [["cellulose", "SIMPLE_CHEMICAL", 44, 53], ["cellulose materials", "TREATMENT", 44, 63], ["anti-infective", "TREATMENT", 76, 90], ["self-sterilizing materials", "TREATMENT", 94, 120], ["both bacteria", "PROBLEM", 129, 142], ["viruses", "PROBLEM", 147, 154]]], ["It can be stated that all antiviral solutions for packaging that include surface coatings and functionalization demand added cost and complexity to the value chain of packaging materials.", [["surface", "ANATOMY", 73, 80], ["all antiviral solutions", "TREATMENT", 22, 45], ["packaging", "TREATMENT", 50, 59], ["surface coatings", "TREATMENT", 73, 89], ["functionalization demand added cost", "TREATMENT", 94, 129]]], ["The volumes, for example, of the global fiber-based packing market exceed more than 400 billion tons annually.", [["the global fiber-based packing market", "TREATMENT", 29, 66], ["volumes", "OBSERVATION_MODIFIER", 4, 11], ["packing", "OBSERVATION_MODIFIER", 52, 59]]], ["This vast industry with a globally fragmented supplier, converter, and end-user market makes impactful value chain innovations difficult to implement [21] .", [["impactful value chain innovations", "PROBLEM", 93, 126], ["globally", "OBSERVATION_MODIFIER", 26, 34], ["fragmented", "OBSERVATION", 35, 45]]], ["The other approaches for inactivation of viruses on surfaces that can be used in the supply chain include ultraviolet germicidal irradiation (UVGI) [34] .", [["ultraviolet germicidal", "CHEMICAL", 106, 128], ["inactivation of viruses on surfaces", "TREATMENT", 25, 60], ["ultraviolet germicidal irradiation", "TREATMENT", 106, 140], ["viruses", "OBSERVATION", 41, 48]]], ["Irradiation of packaging with an appropriate wavelength and light intensity for an effective duration can potentially give a desire effect in warehouses, packaging transport systems, and in final destinations including household use.", [["Irradiation of packaging", "TREATMENT", 0, 24], ["an appropriate wavelength", "TREATMENT", 30, 55]]], ["Other approach includes chemical surface treatments such as Lysol disinfectant, bleach, quaternary ammonium-based products, and phenol-based products [14, 18, 20, 29] .", [["surface", "ANATOMY", 33, 40], ["Lysol", "CHEMICAL", 60, 65], ["quaternary ammonium", "CHEMICAL", 88, 107], ["phenol", "CHEMICAL", 128, 134], ["Lysol", "CHEMICAL", 60, 65], ["ammonium", "CHEMICAL", 99, 107], ["phenol", "CHEMICAL", 128, 134], ["Lysol", "SIMPLE_CHEMICAL", 60, 65], ["bleach", "SIMPLE_CHEMICAL", 80, 86], ["quaternary ammonium-based products", "SIMPLE_CHEMICAL", 88, 122], ["phenol", "SIMPLE_CHEMICAL", 128, 134], ["chemical surface treatments", "TREATMENT", 24, 51], ["Lysol disinfectant", "TREATMENT", 60, 78], ["bleach", "TREATMENT", 80, 86], ["quaternary ammonium", "TREATMENT", 88, 107], ["phenol-based products", "TREATMENT", 128, 149]]], ["The chemical treatments, unfortunately, have many health, safety, and environmental issues that need to be considered.", [["The chemical treatments", "TREATMENT", 0, 23], ["chemical treatments", "OBSERVATION", 4, 23]]], ["In addition, most harsh chemicals do have deteriorative effect on the surface of the packaging material used and the product themselves may also be at risk.", [["surface", "ANATOMY", 70, 77], ["surface", "CELLULAR_COMPONENT", 70, 77], ["deteriorative effect", "PROBLEM", 42, 62], ["the packaging material", "TREATMENT", 81, 103], ["packaging material", "OBSERVATION", 85, 103], ["may also be", "UNCERTAINTY", 136, 147]]], ["If possible, time is one clear antiviral remedy; unfortunately, the environmental conditions including humidity and temperature affect the survival rates of viruses on surfaces.", [["antiviral remedy", "TREATMENT", 31, 47], ["humidity", "TREATMENT", 103, 111]]], ["The possible solution may lay in the intersection of many of these alternative approaches and thus demand further studies.", [["solution", "TREATMENT", 13, 21], ["demand further studies", "TEST", 99, 121], ["possible", "UNCERTAINTY", 4, 12]]], ["Clearly, the need for this knowledge and different elucidations is imminent, and more inventions and innovations are needed to secure the safety and sustainability of our global supply chains.ConclusionsCoronaviruses have shown to survive for extended period, especially in the presence of human secretions and other materials that possibly offer a protective component and promote its persistence.", [["secretions", "ANATOMY", 296, 306], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 203, 216], ["human", "ORGANISM", 290, 295], ["human", "SPECIES", 290, 295], ["human", "SPECIES", 290, 295], ["Coronaviruses", "PROBLEM", 203, 216], ["human secretions and other materials", "PROBLEM", 290, 326], ["a protective component", "TREATMENT", 347, 369], ["secretions", "OBSERVATION", 296, 306]]], ["In this review, the survivability of SARS-CoV-1 and SARS-CoV-2 on the surface of different packaging materials and in different environments has not been reviewed in detail.", [["surface", "ANATOMY", 70, 77], ["SARS", "DISEASE", 37, 41], ["SARS-CoV-1", "ORGANISM", 37, 47], ["SARS-CoV-2", "ORGANISM", 52, 62], ["surface", "CELLULAR_COMPONENT", 70, 77], ["SARS-CoV-1", "SPECIES", 37, 47], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["SARS", "TEST", 52, 56], ["CoV", "TEST", 57, 60], ["different packaging materials", "TREATMENT", 81, 110]]], ["The current COVID-19 pandemic has shown the global importance of understanding of the viral stability and transmittance on packaging surfaces.ConclusionsMore and more consumers are dependent on e-commerce and ordering online and having items delivered directly to their homes.", [["the viral stability", "PROBLEM", 82, 101], ["viral stability", "OBSERVATION", 86, 101], ["surfaces", "OBSERVATION_MODIFIER", 133, 141]]], ["This change in the e-commerce penetration rate also includes the consumer exposure to a variety of packaging materials.", [["the e-commerce penetration rate", "PROBLEM", 15, 46]]], ["The reviewed research data indicate that fast liquid absorption surfaces including cardboard boxes and uncoated other fiber-based packages would potentially have a higher likelihood to inactivate the virus more effectively.", [["cardboard boxes", "DNA", 83, 98], ["research data", "TEST", 13, 26], ["fast liquid absorption surfaces", "TREATMENT", 41, 72], ["cardboard boxes", "TREATMENT", 83, 98], ["uncoated other fiber-based packages", "TREATMENT", 103, 138], ["the virus", "PROBLEM", 196, 205], ["virus", "OBSERVATION", 200, 205]]], ["However, the viral load and the dry form may also be an important aspect influencing the viral stability.", [["the viral load", "TEST", 9, 23], ["viral load", "OBSERVATION", 13, 23], ["may also be", "UNCERTAINTY", 41, 52], ["viral stability", "OBSERVATION", 89, 104]]], ["On the other hand, polymer-coated rigid boxes and carton board may give the longest stability to the virus.", [["carton", "CHEMICAL", 50, 56], ["polymer-coated rigid boxes and carton board", "TREATMENT", 19, 62], ["the virus", "PROBLEM", 97, 106]]], ["The environmental conditions used in the referenced studies show that air-conditioned warehouses and transportation logistics may increase the survivability of the SARS-CoV viruses.", [["SARS", "DISEASE", 164, 168], ["SARS-CoV viruses", "ORGANISM", 164, 180], ["SARS-CoV viruses", "SPECIES", 164, 180], ["the referenced studies", "TEST", 37, 59], ["the SARS-CoV viruses", "PROBLEM", 160, 180]]], ["Thus, many of the researched environmental factors specify higher risk for the modern e-commerce supply chain than the traditional system.", [["the modern e-commerce supply chain", "TREATMENT", 75, 109]]], ["Clearly our review suggests that there is a major lack of existing research related to the transmittal and survivability of the SARS-CoV-2 virus on packaging and the supply chain.", [["SARS", "DISEASE", 128, 132], ["SARS-CoV-2 virus", "ORGANISM", 128, 144], ["CoV-2 virus", "SPECIES", 133, 144], ["SARS-CoV-2 virus", "SPECIES", 128, 144], ["the SARS", "PROBLEM", 124, 132], ["packaging", "TREATMENT", 148, 157], ["chain", "OBSERVATION_MODIFIER", 173, 178]]], ["More data are needed on the impact of different packaging surface properties (including coatings and fillers) to the viral survival.", [["surface", "ANATOMY", 58, 65], ["different packaging surface properties", "TREATMENT", 38, 76], ["coatings and fillers", "TREATMENT", 88, 108], ["the viral survival", "TREATMENT", 113, 131], ["viral survival", "OBSERVATION", 117, 131]]], ["The current increase in funding for SARS-CoV-2 or COVID-19 research is an opportunity to advance the understanding of the role of supply chain and packaging in the survival and transmittance of the SARS-CoV-2 and to further advance the science related to the consumer-related health risks.", [["SARS", "DISEASE", 36, 40], ["SARS", "DISEASE", 198, 202], ["SARS-CoV-2", "ORGANISM", 198, 208], ["SARS-CoV", "SPECIES", 198, 206], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["COVID", "TEST", 50, 55], ["supply chain", "TREATMENT", 130, 142], ["packaging", "TREATMENT", 147, 156], ["the SARS", "TEST", 194, 202], ["increase", "OBSERVATION_MODIFIER", 12, 20]]], ["Based on our findings, the lack of existing information creates unnecessary public fear and the inability to mitigate the global health risks of COVID-19 that we all are facing during these unusual times.", [["COVID", "TREATMENT", 145, 150]]], ["The scientific knowledge of the transmittance and survival of SARS-CoV-2 or other putative future viral sources in the global supply chains and on packaging surfaces is more important now than ever.", [["SARS", "DISEASE", 62, 66], ["SARS-CoV-2", "ORGANISM", 62, 72], ["SARS-CoV", "SPECIES", 62, 70], ["the transmittance", "PROBLEM", 28, 45], ["SARS", "PROBLEM", 62, 66], ["CoV", "PROBLEM", 67, 70]]]], "ae3d170476e867f93595f537046ebcf12ea0e223": [["IntroductionUn Abrazo Para la Familia\u2122 (Abrazo) was developed as a face-to-face intervention to address the cancer knowledge and self-efficacy needs of low-income caregiving co-survivors of cancer [1] , understanding co-survivors to be those affected by the cancer diagnosis of a loved one [2] .", [["cancer", "ANATOMY", 108, 114], ["cancer", "ANATOMY", 190, 196], ["cancer", "ANATOMY", 258, 264], ["Familia\u2122", "CHEMICAL", 30, 38], ["Abrazo", "CHEMICAL", 40, 46], ["cancer", "DISEASE", 108, 114], ["cancer", "DISEASE", 190, 196], ["cancer", "DISEASE", 258, 264], ["cancer", "CANCER", 108, 114], ["cancer", "CANCER", 190, 196], ["cancer", "CANCER", 258, 264], ["IntroductionUn Abrazo Para la Familia\u2122 (Abrazo)", "TREATMENT", 0, 47], ["face intervention", "TREATMENT", 75, 92], ["the cancer", "PROBLEM", 104, 114], ["cancer", "PROBLEM", 190, 196], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 190, 196]]], ["The term caregiver applies to family members and friends who provide a range of support services in caring for an individual with an acute or chronic illness [3] .", [["an acute or chronic illness", "PROBLEM", 130, 157], ["acute", "OBSERVATION_MODIFIER", 133, 138]]], ["Informal caregivers are predominately female [4] and experience stress at levels that can harm them physically and psychologically [5] [6] [7] .IntroductionWhile the role of the family in cancer care and the stress associated with a cancer diagnosis has been extensively summarized and documented over the past two decades [6] , consensus exists that we still need to better understand the cultural needs of and differences among caregivers [5] .", [["cancer", "ANATOMY", 188, 194], ["cancer", "ANATOMY", 233, 239], ["cancer", "DISEASE", 188, 194], ["cancer", "DISEASE", 233, 239], ["cancer", "CANCER", 188, 194], ["cancer", "CANCER", 233, 239], ["stress at levels", "PROBLEM", 64, 80], ["cancer care", "TREATMENT", 188, 199]]], ["Abrazo was developed with cultural context and other social determinates of health factors in mind [8] .", [["Abrazo", "CHEMICAL", 0, 6], ["Abrazo", "CHEMICAL", 0, 6], ["Abrazo", "TREATMENT", 0, 6]]], ["Abrazo is a psychoeducational evidence-based intervention that has demonstrated significant outcomes in cancer knowledge and self-efficacy [2, [9] [10] [11] for low-income caregiving co-survivors of cancer, as well as for survivors or care recipients [12] .A Daughter's Experience: Parental CancerUsing autoethnography, I first reflected on the role of the family in cancer and within the context of culture and socioeconomic status-my motivation being my experience as a daughter of a man with prostate cancer [13] .", [["cancer", "ANATOMY", 104, 110], ["cancer", "ANATOMY", 199, 205], ["cancer", "ANATOMY", 367, 373], ["prostate cancer", "ANATOMY", 495, 510], ["Abrazo", "CHEMICAL", 0, 6], ["cancer", "DISEASE", 104, 110], ["cancer", "DISEASE", 199, 205], ["cancer", "DISEASE", 367, 373], ["prostate cancer", "DISEASE", 495, 510], ["Abrazo", "CHEMICAL", 0, 6], ["cancer", "CANCER", 104, 110], ["cancer", "CANCER", 199, 205], ["cancer", "CANCER", 367, 373], ["man", "ORGANISM", 486, 489], ["prostate cancer", "CANCER", 495, 510], ["man", "SPECIES", 486, 489], ["Abrazo", "TREATMENT", 0, 6], ["based intervention", "TREATMENT", 39, 57], ["significant outcomes in cancer", "PROBLEM", 80, 110], ["cancer", "PROBLEM", 199, 205], ["culture", "TEST", 400, 407], ["prostate cancer", "PROBLEM", 495, 510], ["significant", "OBSERVATION_MODIFIER", 80, 91], ["cancer", "OBSERVATION", 104, 110], ["cancer", "OBSERVATION", 199, 205], ["cancer", "OBSERVATION", 367, 373], ["prostate", "ANATOMY", 495, 503], ["cancer", "OBSERVATION", 504, 510]]], ["As with too many other low-income folks [8] , my father had been diagnosed with a late-stage cancer and died 2.5 years afterward.", [["late-stage cancer", "ANATOMY", 82, 99], ["late-stage cancer", "DISEASE", 82, 99], ["late-stage cancer", "CANCER", 82, 99], ["a late-stage cancer", "PROBLEM", 80, 99], ["stage", "OBSERVATION_MODIFIER", 87, 92], ["cancer", "OBSERVATION", 93, 99]]], ["I certainly felt that for all my efforts, my \"caregiving\" was too little, too late.A Daughter's Experience: Parental CancerSubsequent to his death in 2000, and given my professional background in rehabilitation research, I applied for and was accepted to a 1-year fellowship program beginning in January 2002 with the Cancer, Culture and Literacy (CCL) Institute [14] at the H. Lee Moffitt Cancer Center and Research Institute.", [["Cancer", "ANATOMY", 318, 324], ["death", "DISEASE", 141, 146], ["Cancer", "DISEASE", 318, 324], ["Cancer", "DISEASE", 390, 396], ["Cancer", "CANCER", 318, 324], ["the Cancer", "PROBLEM", 314, 324], ["Cancer", "OBSERVATION", 318, 324], ["Cancer", "OBSERVATION", 390, 396]]], ["According to Meade, \"the goal of the Institute was to improve care across the continuum of cancer control by enhancing the skills of researchers responsible for creating multicultural, multilingual, and literacy sensitive interventions and communications for a demographically changing population\" (p.4) [14] .A Daughter's Experience: Parental CancerA Caregiving Experience and the Abrazo Model I learned through the CCL Institute that when family members are called upon to participate in making treatment decisions, multiple factors may influence their ability to fully participate.", [["cancer", "ANATOMY", 91, 97], ["cancer", "DISEASE", 91, 97], ["cancer", "CANCER", 91, 97], ["cancer control", "TREATMENT", 91, 105], ["literacy sensitive interventions", "TREATMENT", 203, 235], ["cancer", "OBSERVATION", 91, 97]]], ["Family members may find that they do not have the health literacy (i.e., cancer-related vocabulary and knowledge), problem-solving, or communication skills to most effectively support their relative, or to address the overarching family challenges that cancer can present.", [["cancer", "ANATOMY", 73, 79], ["cancer", "ANATOMY", 253, 259], ["cancer", "DISEASE", 73, 79], ["cancer", "DISEASE", 253, 259], ["cancer", "CANCER", 73, 79], ["cancer", "CANCER", 253, 259], ["cancer", "OBSERVATION", 253, 259]]], ["Words we know may have different meanings in an oncology context-one example from my personal experience as my dad's caregiver-I was told to expect a \"bleeding event.\"", [["bleeding", "DISEASE", 151, 159], ["a \"bleeding event", "PROBLEM", 148, 165]]], ["I truly had no idea what to expect-an ebola-type bleeding?", [["bleeding", "DISEASE", 49, 57], ["an ebola", "PROBLEM", 35, 43], ["type bleeding", "PROBLEM", 44, 57], ["ebola", "OBSERVATION", 38, 43], ["bleeding", "OBSERVATION", 49, 57]]], ["We may not know how to spell terminology related to cancer treatment so note-taking is a problem.", [["cancer", "ANATOMY", 52, 58], ["cancer", "DISEASE", 52, 58], ["cancer", "CANCER", 52, 58], ["cancer treatment", "TREATMENT", 52, 68], ["cancer", "OBSERVATION", 52, 58]]], ["Low-income people can be very proud people and not accept \"handouts\" or feel inclined to sit with a social worker to complete applications for free or reduced-price medicines.", [["people", "ORGANISM", 11, 17], ["people", "ORGANISM", 36, 42], ["people", "SPECIES", 11, 17], ["people", "SPECIES", 36, 42], ["reduced-price medicines", "TREATMENT", 151, 174]]], ["Working with siblings to determine \"who pays\" when a low-income parent has cancer can be difficult.", [["cancer", "ANATOMY", 75, 81], ["cancer", "DISEASE", 75, 81], ["cancer", "CANCER", 75, 81], ["cancer", "PROBLEM", 75, 81], ["cancer", "OBSERVATION", 75, 81]]], ["Apart from terminology, my experience was that communication was not always appropriate-from an oncologist asking my father in my presence about his sexual function to then suggesting a physical exam before I could scramble out of the room.", [["a physical exam", "TEST", 184, 199]]], ["Indeed, the diagnosing urologist told me he had a great deal of difficulty giving a cancer diagnosis to his patients.", [["cancer", "ANATOMY", 84, 90], ["cancer", "DISEASE", 84, 90], ["cancer", "CANCER", 84, 90], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116]]], ["The challenges my family faced were many and, as I learned later, reflective of other low-income families-perhaps especially those uninsured families whose first encounter with the medical establishment brings along a cancer diagnosis.", [["cancer", "ANATOMY", 218, 224], ["cancer", "DISEASE", 218, 224], ["cancer", "CANCER", 218, 224], ["cancer", "OBSERVATION", 218, 224]]], ["A few of those challenges: [13] .", [["few", "OBSERVATION_MODIFIER", 2, 5]]], ["We needed more time than that.A Daughter's Experience: Parental CancerAfter my father's death from prostate cancer, reflecting upon these factors was the impetus that led me, as a researcher, to ask if these experiences were indeed uniquely my own.", [["prostate cancer", "ANATOMY", 99, 114], ["death", "DISEASE", 88, 93], ["prostate cancer", "DISEASE", 99, 114], ["prostate cancer", "CANCER", 99, 114], ["prostate cancer", "PROBLEM", 99, 114], ["prostate", "ANATOMY", 99, 107], ["cancer", "OBSERVATION", 108, 114]]], ["Did others from low-income families experience the same stress and distress due to their lack of preparedness when facing the cancer diagnosis of a loved one?", [["cancer", "ANATOMY", 126, 132], ["cancer", "DISEASE", 126, 132], ["cancer", "CANCER", 126, 132], ["the same stress", "PROBLEM", 47, 62], ["distress", "PROBLEM", 67, 75], ["cancer", "OBSERVATION", 126, 132]]], ["I wanted to use my rehabilitation research skills, coupled with my personal experience as daughter of a man with prostate cancer, to understand if other low-income families experienced a cancer diagnosis as my family had.A Daughter's Experience: Parental CancerI received a NIH NCI-sponsored Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Senior Fellowship during 2007-2009.", [["prostate cancer", "ANATOMY", 113, 128], ["cancer", "ANATOMY", 187, 193], ["prostate cancer", "DISEASE", 113, 128], ["cancer", "DISEASE", 187, 193], ["man", "ORGANISM", 104, 107], ["prostate cancer", "CANCER", 113, 128], ["cancer", "CANCER", 187, 193], ["man", "SPECIES", 104, 107], ["prostate cancer", "PROBLEM", 113, 128], ["prostate", "ANATOMY", 113, 121], ["cancer", "OBSERVATION", 122, 128], ["cancer", "OBSERVATION", 187, 193]]], ["The NRSA allowed me to obtain the data needed to develop a psychoeducational, skill-building, and tailored intervention designed to increase the quality of life, including well-being and productivity, of low-income female family members who were providing socioemotional and/or financial support to a cancer survivor relative who had either cervical or breast cancer-this intervention became Abrazo [2, [9] [10] [11] [12] .", [["cancer", "ANATOMY", 301, 307], ["cervical", "ANATOMY", 341, 349], ["breast cancer", "ANATOMY", 353, 366], ["cancer", "DISEASE", 301, 307], ["breast cancer", "DISEASE", 353, 366], ["Abrazo", "CHEMICAL", 392, 398], ["Abrazo", "CHEMICAL", 392, 398], ["cancer", "CANCER", 301, 307], ["cervical", "ORGANISM_SUBDIVISION", 341, 349], ["breast cancer", "CANCER", 353, 366], ["Abrazo [2, [9] [10] [", "SIMPLE_CHEMICAL", 392, 413], ["tailored intervention", "TREATMENT", 98, 119], ["cervical or breast cancer", "PROBLEM", 341, 366], ["this intervention", "TREATMENT", 367, 384], ["Abrazo", "TEST", 392, 398], ["cervical", "ANATOMY", 341, 349], ["breast", "ANATOMY", 353, 359], ["cancer", "OBSERVATION", 360, 366]]], ["By first researching the needs of local low-income families facing cancer, irrespective of stage, Abrazo was then developed to meet the specific needs of these family members who had reported that they (1) needed more information about cancer, (2) had trouble communicating with their provider, and (3) needed information regarding resources available to them [1] .A Daughter's Experience: Parental CancerHaving obtained my doctorate in rehabilitation at The University of Arizona (UA) in Tucson in 1985 [13] , I returned to UA in 2007 via the NRSA to conduct the research leading to the development of Abrazo.", [["cancer", "ANATOMY", 67, 73], ["cancer", "ANATOMY", 236, 242], ["cancer", "DISEASE", 67, 73], ["cancer", "DISEASE", 236, 242], ["UA", "CHEMICAL", 525, 527], ["Abrazo", "CHEMICAL", 603, 609], ["cancer", "CANCER", 67, 73], ["cancer", "CANCER", 236, 242], ["cancer", "PROBLEM", 67, 73], ["Abrazo", "TREATMENT", 98, 104], ["cancer", "PROBLEM", 236, 242], ["UA", "TEST", 525, 527], ["Abrazo", "TREATMENT", 603, 609], ["cancer", "OBSERVATION", 67, 73]]], ["I envisioned Abrazo, as a rehabilitation-informed intervention, as a platform for developing psychosocial oncology evidence-based interventions for families affected by cancer that would also serve as community outreach strategies for low-income and underserved populations [8] .", [["cancer", "ANATOMY", 169, 175], ["Abrazo", "CHEMICAL", 13, 19], ["cancer", "DISEASE", 169, 175], ["cancer", "CANCER", 169, 175], ["a rehabilitation", "TREATMENT", 24, 40], ["cancer", "PROBLEM", 169, 175]]], ["\"Over the years the philosophy of rehabilitation has remained focused on the belief that all people are unique and possess dignity and worth\" (p.192) [16] .", [["people", "ORGANISM", 93, 99], ["people", "SPECIES", 93, 99], ["rehabilitation", "TREATMENT", 34, 48]]], ["Rehabilitation philosophy embraces the importance of involving family when coping with a chronic illness and utilizing group methods for psychoeducational interventions [13] .", [["chronic illness", "DISEASE", 89, 104], ["a chronic illness", "PROBLEM", 87, 104], ["group methods", "TREATMENT", 119, 132], ["psychoeducational interventions", "TREATMENT", 137, 168]]], ["Rehabilitation principles acknowledge the importance of education, skills-teaching, and strength-based psychosocial support as components of interventions [17] .Benefit Through ABRAZOWhile rehabilitation informed, Abrazo is conceptualized as a preventive intervention [2] .", [["Abrazo", "CHEMICAL", 214, 220], ["Rehabilitation principles", "TREATMENT", 0, 25], ["psychosocial support", "TREATMENT", 103, 123], ["ABRAZOWhile rehabilitation", "TREATMENT", 177, 203], ["Abrazo", "TREATMENT", 214, 220], ["a preventive intervention", "TREATMENT", 242, 267]]], ["We use the term preventive intervention in line with literature that indicates that informational approaches can prevent the stress, and clinical depression and anxiety associated with the distress of a cancer diagnosis among families facing cancer [18] .", [["cancer", "ANATOMY", 203, 209], ["cancer", "ANATOMY", 242, 248], ["depression", "DISEASE", 146, 156], ["anxiety", "DISEASE", 161, 168], ["cancer", "DISEASE", 203, 209], ["cancer", "DISEASE", 242, 248], ["cancer", "CANCER", 203, 209], ["cancer", "CANCER", 242, 248], ["the term preventive intervention", "TREATMENT", 7, 39], ["the stress", "PROBLEM", 121, 131], ["clinical depression", "PROBLEM", 137, 156], ["anxiety", "PROBLEM", 161, 168], ["the distress", "PROBLEM", 185, 197], ["a cancer", "PROBLEM", 201, 209], ["cancer", "OBSERVATION", 203, 209]]], ["The needs that Abrazo addresses include not only providing knowledge and basic understanding about cancer, but also skill development for use of supportive services, using tools needed to understand cancer stage, and skills to address site-specific issues with their oncology team.Benefit Through ABRAZOAbrazo participants are typically informal family caregiving co-survivors of cancer who provide a range of services [3] .", [["cancer", "ANATOMY", 99, 105], ["cancer", "ANATOMY", 199, 205], ["cancer", "ANATOMY", 380, 386], ["cancer", "DISEASE", 99, 105], ["cancer", "DISEASE", 199, 205], ["cancer", "DISEASE", 380, 386], ["cancer", "CANCER", 99, 105], ["cancer", "CANCER", 199, 205], ["cancer", "CANCER", 380, 386], ["participants", "SPECIES", 310, 322], ["Abrazo", "TREATMENT", 15, 21], ["cancer", "PROBLEM", 99, 105], ["supportive services", "TREATMENT", 145, 164], ["cancer stage", "PROBLEM", 199, 211]]], ["Further, as per my personal example, a caregiver may provide support by making and driving a loved one to appointments, paying bills, or keeping records.Benefit Through ABRAZOIn chronic illnesses such as cancer, family caregivers are often involved in shared decision-making regarding treatment.", [["cancer", "ANATOMY", 204, 210], ["chronic illnesses", "DISEASE", 178, 195], ["cancer", "DISEASE", 204, 210], ["cancer", "CANCER", 204, 210], ["ABRAZOIn chronic illnesses", "PROBLEM", 169, 195], ["treatment", "TREATMENT", 285, 294]]], ["Recognition of this shared decision-making requires strategies for upholding the autonomy of the patient while recognizing and respecting family input and contributions [19] .", [["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 97, 104]]], ["Given the two decades since the turmoil of my father's diagnosis from prostate cancer, and his subsequent death from the disease, it is my lasting hope that Abrazo can continue to benefit others, ensuring everyone's needs are being met in the family touched by cancer [20] .", [["prostate cancer", "ANATOMY", 70, 85], ["cancer", "ANATOMY", 261, 267], ["prostate cancer", "DISEASE", 70, 85], ["death", "DISEASE", 106, 111], ["Abrazo", "CHEMICAL", 157, 163], ["cancer", "DISEASE", 261, 267], ["prostate cancer", "CANCER", 70, 85], ["Abrazo", "SIMPLE_CHEMICAL", 157, 163], ["cancer", "CANCER", 261, 267], ["prostate cancer", "PROBLEM", 70, 85], ["his subsequent death", "PROBLEM", 91, 111], ["the disease", "PROBLEM", 117, 128], ["Abrazo", "TREATMENT", 157, 163], ["prostate", "ANATOMY", 70, 78], ["cancer", "OBSERVATION", 79, 85]]], ["We leave pathology to the cancer and do not search for it among the dynamics impacting family members facing a loved one with cancer.ConclusionIn the 20 years since I began to process my father's death, three areas of overlapping clinical, educational, and research advances have informed the continued work of Abrazo: (1) progress toward meeting the needs of low-income people within the context of high-cost cancer treatment, (2) continued understanding of co-survivor impact on survivor well-being, and (3) the ubiquity of technology utilized by families and telemedicine.ConclusionThe Affordable Care Act (ACA) arrived with the hope of preventive and wellness health care to all [23] .", [["cancer", "ANATOMY", 26, 32], ["cancer", "ANATOMY", 126, 132], ["cancer", "ANATOMY", 410, 416], ["cancer", "DISEASE", 26, 32], ["cancer", "DISEASE", 126, 132], ["death", "DISEASE", 196, 201], ["cancer", "DISEASE", 410, 416], ["cancer", "CANCER", 26, 32], ["cancer", "CANCER", 126, 132], ["people", "ORGANISM", 371, 377], ["cancer", "CANCER", 410, 416], ["people", "SPECIES", 371, 377], ["the cancer", "PROBLEM", 22, 32], ["cancer", "PROBLEM", 126, 132], ["high-cost cancer treatment", "TREATMENT", 400, 426], ["cancer", "OBSERVATION", 26, 32], ["cancer", "OBSERVATION", 126, 132], ["cancer", "OBSERVATION", 410, 416]]], ["My personal hope became that a cancer diagnosis was then not the first encounter for a low-income family with a health care team.", [["cancer", "ANATOMY", 31, 37], ["cancer", "DISEASE", 31, 37], ["cancer", "CANCER", 31, 37], ["cancer", "OBSERVATION", 31, 37]]], ["While ACA has now been in place for a decade, we still see that the intersection of race and ethnicity with income status requires focused attention to eliminate disparities [24] .", [["ACA", "PROTEIN", 6, 9]]], ["Some would argue that the economic implications of cancer may well trump all other concerns [25] .", [["cancer", "ANATOMY", 51, 57], ["cancer", "DISEASE", 51, 57], ["cancer", "CANCER", 51, 57], ["cancer", "PROBLEM", 51, 57], ["cancer", "OBSERVATION", 51, 57]]], ["Financial toxicity is now being discussed in regard to cancer treatment [26, 27] .ConclusionWe have understood that social support can impact survivor outcomes [28] .", [["cancer", "ANATOMY", 55, 61], ["toxicity", "DISEASE", 10, 18], ["cancer", "DISEASE", 55, 61], ["cancer", "CANCER", 55, 61], ["Financial toxicity", "PROBLEM", 0, 18], ["cancer treatment", "TREATMENT", 55, 71]]], ["Researchers continue to look at the implications of social support, for instance, caregiver psychological states upon survivor outcomes-recently adding the dynamic of SES-related stress and finding that caregiver stress would indeed predict depression and anxiety in the survivor [29] .ConclusionIn 2006, we wrote of the promise of telemedicine to allow the underserved, especially those in rural and remote areas, access to health care advocates and to specialized medical knowledge [30] .", [["depression", "DISEASE", 241, 251], ["anxiety", "DISEASE", 256, 263], ["depression", "PROBLEM", 241, 251], ["anxiety", "PROBLEM", 256, 263], ["telemedicine", "TREATMENT", 332, 344]]], ["Importantly, we also noted that telemedicine could be a conduit for providing cultural expertise in an intervention as well.", [["a conduit", "TREATMENT", 54, 63], ["an intervention", "TREATMENT", 100, 115], ["conduit", "OBSERVATION", 56, 63]]], ["Now, 14 years later, telemedicine is no longer just a promise nor is the technology associated with it.", [["no longer", "UNCERTAINTY", 37, 46]]], ["This was not the case in 1998 when my father was diagnosed with prostate cancer.", [["prostate cancer", "ANATOMY", 64, 79], ["prostate cancer", "DISEASE", 64, 79], ["prostate cancer", "CANCER", 64, 79], ["prostate cancer", "PROBLEM", 64, 79], ["prostate", "ANATOMY", 64, 72], ["cancer", "OBSERVATION", 73, 79]]], ["Seeing each other meant a flight.ConclusionTelehealth has become far more common than we might like during the time of COVID-19.", [["COVID-19", "CHEMICAL", 119, 127], ["COVID", "TEST", 119, 124]]], ["The digitization of Abrazo is underway so that families may access the intervention online if faceto-face is not an option.", [["Abrazo", "TREATMENT", 20, 26], ["the intervention", "TREATMENT", 67, 83]]], ["Thus, whether Abrazo is delivered in person or via some form of telehealth, an embrace, a virtual hug for the low-income family facing cancer, continues to be relevant and needed.", [["cancer", "ANATOMY", 135, 141], ["Abrazo", "CHEMICAL", 14, 20], ["cancer", "DISEASE", 135, 141], ["Abrazo", "CHEMICAL", 14, 20], ["Abrazo", "SIMPLE_CHEMICAL", 14, 20], ["cancer", "CANCER", 135, 141], ["person", "SPECIES", 37, 43], ["cancer", "OBSERVATION", 135, 141]]]]}